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aOOTER I 
'!he primary qoal of this dissertatiai research has been to 
determine the potential role of interleukin 1 (IL-1) in the develop-
ment of protective inm.me responses to an experimental lyitplana. '!his 
biological response ll'Odifier (BRM) is considered for study because of 
its many known intmunoregulatory roles (64,78), incl~ the ability 
to augment the inm.me response in defined antigenic systems (285, 
312). However, no previous reports have den¥:>nstrated a direct role 
for IL-1 in the develcpnent of inmmity to experimental neoplasia. 
'!he experimental tunw:>r JOOde1 enployed in this study is the Eir4 
lyzrphana which is syn_;eneic in C57Bl/6 mice ani results in high 
llk)rtality (39,100). In this system, mice can be protected f:ran a 
nonnally fatal dose of the weakly inummogenic Eir4 lynphama (101) by 
local administration of Cocynebacterium paryum ( 183) • However, these 
animals show no deronstrable tun:>r imrm.mity since they will succumb 
to a secoIXl challen;re of the tunw:>r. It has been the p.irpose of this 
study to determine whether administratiai of IL-1 can enhance anima1 
survival or augment the developnent of imrm.mity to the Eir4 lyitpnna. 
'!he remaining objective of this :research was to assess the cx:rapart-
ments of the imnnme system which may be m::xiul.ated by IL-1 leadin:j to 
the establishment of tunw:>r imrm.mity. 'Ib accomplish this qoal, in 
vitro analysis of splenic ani lymphatic tissues of treated anilnal.s 
has been perfonned to assess a possible mechanism( s) by which IL-1 
1 
2 
may m::xiulate the imm..me response to the Eir-4 lynphana. Several 
inum.me correlates likely to be associated with the developnent of 
ttnoor immunity ani, therefore, urmr scrutiny in this project, were 
Eir-4 ttnoor specific cytotoxic T cells, natural killer cells {NK) , ani 
hunmal antibody response to the Eir-4 lynphana. Also, possible 
m::xiulation by IL-1 of lyqiloid pcp.1].ations ani their proliferative 
responsiveness to the Eir-4 lynphana were investigated. All of these 
inmm:>logical parameters have been reported by other investigators to 
be augmented by IL-1 am may urmrlie the mechanism by which IL-1 
leads to the augmentatioo of turoor imnamity in the Eir-4:C57Bl/6 
experimental no:lel. 
CHAPI'ER II 
A. Adjuvant Effects of Coeynebacterium paryum 
over the last twenty-five years, a wide variety of immunostim-
ulants have been shown to effect the growth of synJeneic transplant-
able tunm's in mice. startirg in the early 19608 with zyioosan (yeast 
cell walls) (233) arxi Bacillus calmette-Guerin (ED;) (231), this list 
of inm.mostimul.ants has been exparxied to inclu:ie viable bacteria, 
bacterial by-products, nonviable bacteria arxi chemically defined 
~ (17). 
'!he first Wication that ~ paryum would be<xme an :i.nportant 
research tool as an .illm.mological stinulant was dena1strated by 
Halpern et al. in 1964, when they fa:all c. paryum to be a potent 
stinulator of the reticulo-emothel.ial system ( 109) • Many investiga-
tors have since verified these observations (123,243,286,294) with 
c. parvum treated mice showinJ increases in liver arxi spleen weights 
(5,109,188,197,228) as well as an increased ability to clear intra-
venously injected cartx>n. c. parvum has been shown to exert adjuvant 
effects on antibody production, in:iuction of delayed type hypersensi-
tivity (5,25,223), arxi may be satisfactorily substituted for the 
mycobacterial canponent of F.reurd's cx:arplete adjuvant {223). c. 
parvum treatment enhances protection against protozoal (226) , viral 
( 143) arxi bacterial infection (3) , as well graft-versus-host disease 
(122). '!here is abumant evidence to Wicate these effects are 
3 
attributable to augmentation of macrophage function (304). Aside 
from enhanced macrophage function, subcutaneous (307) arrl systemic 
( 62) administration of c. parvum stimulates macrqtlage colony pro-
duction by bone marrow cells, enhances proliferation of granulo-
poietic cells, and increases the percentage of ncnlifferentiated 
cellular fo:nns in the bane marrow (18,262). 
4 
Treatment with c. pa:rwm has also been shown to retard the 
growth of subcutaneous am peritaleal. tuna:s in mice (30' 107' 198' 270' 
313) • 'lliere is lmlCh S\JRX)rt for the view that macrqilage stbnlation 
is the mechanism responsible for the bacterial suspensions• effec-
tiveness in enharx:irq the host's defence against neoplastic disease 
(162). Evidel'lce has .iniioated that augmentation of NK activity is a 
potential mechanism of ~ parwm antituioor activity (200) , altllolgh a 
mre recent report has dena1strated suppression of NK activity by the 
bacterium (86) • 'lhe role of the macrqtlage in the expression of 
inmamity to tuna:s was initially described by st\:dies in· which peri-
toneal macrophage cell suspensions, taken fran inmmized dooors, were 
able to exert suppressive effects on syrqeneic tuioors in mice (232) • 
'Ihese macrophages were also fami to inhibit the growth of tuioor 
cells in yiY:Q (15). Macrophage mediated tuioor cell killin;J has been 
shown to be a property of highly activated macrqilages (139) • Perito-
neal macrophages, i?Dioed by irritants such as thioglyoolate,· appear-
ed to be partially activated showin;J increased adherence am pino-
cytosis ( 188) • However, these macrophages did not becane cytotoxic 
for tuioor cells until fUlly activated with various bacteria or erxio-
toxin (37) • Similarly, macrqtlages obtained fran c. parvum treated 
5 
anilllals, When implanted either subcutaneously or intraperitoneally 
( i. p.) with m.irine fibrosaroana 'tunK:>r cells, caused a significant 
reductiai in 'tunK:>r growth (246). 'Ihese macrqilages, When incubated 
in y1:Q;;:Q with syn:Jelleic 'tunK:>r cells, also demnstrated cytostatic 
(108) as well as cytotoxic activity for 'tunK:>r cells (16). Since both 
nude (248,315) arxi germ-free mice (275) dem:Jnstrate equal anti'tunK:>r 
effectiveness, it appeared that this augmented inumme functiai was a 
direct result of macrqha~ parvum interactiai. Additiaial evi-
dence implicated the naiocytejmacrcplage precursor as the target cell 
for the anti'tunK:>r effect of c. parvum. Whole body irradiatiai of 
mice shortly before ~ parvum injectiai pnwents the develqment of 
resi.sta?x:le to tumr challerge, whereas irradiatiai after treatment 
oanpletely ~the hun¥:>ral response to c. parvum (30)' bit 
failed to abrogate the c. parvum anti'tunK:>r effect (30,200). '!his 
suggests that the relevant cell arose fran a radiosensitive, rapidly 
diviclirq precursor whose mature camterpart was radioresistant. '!his 
is consistent with the characteristics of the ioonocyt.ejmacrqi'lage 
cell ( 18) • Cctrpilatiai of this data has lead to the cxn::llusiai that 
the activated macrqi'lage is the CX111t1L>11 mediator of biological effects 
of c. parvum (29) • 
Although c. parvum has been used as an inmrunotherapeuic anti-
carx::er agent, the oanponent(s) of this organism responsible for these 
activities has not yet been identified. '!he effects of varioos chem-
ical treatments ai the pat:eooy of c. parvum extracts have suggested 
that the active oanponent is cartxilydrate in nature (4,40,250,258), 
bit may require oanplete cell integrity for full activity (40) since 
6 
purified cell walls retain antigenicity, :rut do not retain antitunm' 
activity (257) • 
Althalgh macr:qi1age activaticm may play an inportant role in 
tunor rejecticm, these chemical stuiles have shown that cytotoxic 
macrq:hages do not appear to be sufficient for the overall antitum:>r 
activity of~ parvum (40). Peritoneal exlX!ate cells frail mice 
treated with the whole organism or the "light residue" (primarily 
cell walls am cell walls oontaininJ protoplasm) were highly activ-
ated, as deronstrated by their ability to nonspecifically kill tunor 
cells .in~. However, \totlen the "light residue" was treated with 
metaperiodate, which redlices au:Dahydrate content of the residue, the 
high macr:qi1age activatin;J prq>erties were maintained, :rut the anti-
tuioor activity diminished significantly. 'lhese results suggest that 
macrq:hage activaticn is not the only property of c. parnnn require:i 
to iniuce full .in vivo antitunm' activity ( 40) • 
It was noted that followin;J systemic injection (intravenous) of 
c. parnnn in mice, there was widespread proliferation, redistribution 
am m:>bilization of lynpioid cells (42) with associated splencmegaly, 
hepatamegal.y am increased lung (5) am lyrrph node (42,188,197) 
weights. on the other bani, there is little charge in spleen am 
liver weights followin;J subcutaneous injection of c. parnnn, although 
there is an enlargement of lyrrph nodes drainin;J the subcutaneous 
injection site (270,294), with an associated increase in lynpiocyt:e 
cell number in the drainin;J nodes (51). 
Investigaticm of this ~ parvum mediated lYJl'Ploid m:>bilizaticm 
lead to the deloonstraticm of c. parvum mediated adjuvant activity in 
7 
mice as de.nalst.rated by an anplification in the antilxxfy response to 
both thynus depenient IgM-IgG responses (24,130,305) an:i the thynus 
iniepeDjent IgM response (60,123,130,302). I.ocal adjuvant effects of 
~ paryum have been shown When the injection of sheep red blood cells 
admixed with .C.:. paryum increased the number of direct plaque formirg 
cells in drainin;J lynph nodes (201) • Enhanced antigen presentation 
of antigen to ly.trplocytes seen by c. parwm stimulated macrq:hages 
(230,307) may explain these lynphocytic stimulatoey effects of c. 
parvum. 
T cell responsiveness may be stim.ll.ated or inhibited, depemin] 
on the route or c. paryum administration. Systemic c. parvum treat-
ment is usually associated with depression of cell-mediated .iJmllne 
responses (7 ,272), possibly due to an effective depletion of sensit-
ized cells traR;led in the c. parvum stim.ll.ated spleen (272). on the 
other hard, enhancanent of delayed type hypersensitivity (mH) re-
sults after subcutaneaJs injectiai with a wide raBJ8 of ~ parvum 
doses (176.271,275,294). '!he activatiai of macrqilaqes in regional 
lynph nodes ag;>ears to modulate the differentiatiai an:i claial.ization 
of neamy T cells, with the dani.nant effect bein:j the inhibition of 
the qeneratiai of specific T suppressor cells (176). 'Iherefore, the 
increase in ioonocyte numbers (18) an:i furx::tional activity (93), both 
in accessory cell function an:i lyirphocyte subset modulation, may 
augment antigen presentation an:i lynphocytic responses at the site of 
macrqi'lage activation. SUdl mechanisms may mediate the turoc>r inm.m-
ity associated with .C.:. parvum therapy. 
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In nurine systems, the efficacy of c. parvum antitumr therapy 
has varied greatly depeMirg on several parameters (201), many simi-
lar to the parameters mentioned earlier in this review reganiin;J ioore 
general JOOdulatian of illmlrv:>loqical responses. Several .inp:>rtant 
therapeutic parameters to oonsider ~ utilizirg this bacterial 
agent are the rcute of injection (201), the size am locatiai of the 
tumr (52,201), the anomt of bacteria injected (28,223), am the 
imnumogenicity of the tumr in the host-tunm' no:1el (17 ,245). Depen-
din;J on the tumr no:1el en-ployed, systemic adminstration of c. parvum 
has been shown to be an effective therapeutic agent when sirgle doses 
were given f:ran one week prior (30,270) to two weeks (165) after 
tumr challen]e. c. parvum therapy was also effective when tum::>r/ 
bacteria admixtures were injected simultaneously (248,295). 
Against established tumrs, systemic c. parvum treatment is 
JOOSt effective against small tunm' masses when injected soon after 
tumr inoculation; multiple~ parvum doses have generally not 
in::reased effectiveness (199,286). Althoogh tunor regressions have 
been achieved with intravenous therapy, this type of effect is not 
usually attainable with poorly inummogenic tumrs (199) • 
IDcalized tunor therapy, with direct injection of c. parvum 
into growirg solid tu:mr, have resulted in oc:m:plete am permanent 
regressions in many different tunx:>r m::xiels (33,106,163,255,294). In 
sane cases, metastasized tun¥:>r have been shown to regzess as well 
(163, 165). SUbcutaneous injections of c. parvum at sites distant 
f:ran the t.um::>r usually have minimal effect on tum::>r growth, whereas 
marked inhibition is seen after injection near the region of t:uJoor 
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growth (271, 314) • Unlike systemic treatment, which a~ to favor 
the generation of n:mspecific effector mechanisms (i.e. activate:i 
macrophages (234,270), natural killer cells (229)), intralesional c. 
parvum therapy ai;pears to generate T cell mediate:i antituioor inm.mity 
since this antituioor action requires the preseooe of a fUnctional T 
cell system (28,80,296,315). Animals treate:i in this fashion are not 
only able to regress the treate:i tunor lesion, but also regress un-
treate:i blroc>rs at distant sites which are in early stages of develop-
ment (202). Rejection of distant site tuioors has been associate:i 
with the augmented production of cytolytic T cells in the lynph rxxies 
drainirq the site of therapeutic injection (202). Animals, which 
have regressed their tunDrs after intralesialal. ~ parwm therapy, 
are subsequently able to specifically reject a similar tunDr ilrplant 
(273,295) am possess T cells capable of passively transferrinj tunx:>r 
resistance to unimna.mized imividuals (295,296). 
Mice, which have rejected tunDrs that have devel~ fran tuioor 
cells admixed with c. parvum, are similarly am specifically imnune 
(164). However, the ability to irxiuoe T cell specific tuioor inm.mity 
again awears to be llldte:i to the ioore highly ilrm.ln:lgenic blroc>rs 
(80,249). Nonspecific mechanisms appear to protect animals fran 
weakly inmmogenic tuioors followirg intralesional c. parvum therapy, 
consequently animals sw:vivinJ a weakly imnrunogenic tuioor challerge 
are unable to successfully sw:vive a secarxl, identical tuioor chal-
lerge. 
'!he Eir-4 lynphana, the tuioor no:ie1 enployed in this study, is 
an exanple of a weakly i.mmurx:>genic tuioor (39,100). '!his tuioor is 
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:refractory to inmmoadjuvant therapeutic aqents such as viable 
lf{OC!bacterium bovis, :ea;, am starmrd :regimens of nawiable ~ 
parnnn (94,289). More riqoroJS ad.juvant therapy protoools with c. 
parnnn (183) am Blastatr/OeS dentlatitidis (190) have enabled animals 
to respotXl to the Eir-4 l:yitplana yieldin;J high sw:vival rates followr-
in;J tuioor chal.let)le. HoiMver, animals sw:vivin] this initial 'blloor 
c:hallen;Je are unable to dem:lnstrate 'blloor specific immunity upon Eit-4 
:rechallen;Je (183). 'lhese results are markedly different when highly 
inummogenic tunm' nv:xiels are treated with adjuvant type immunother-
apy, where the develq:ment of tunm- specific immunity is seen in pro-
tected animals (174,202). '!he lack of an effective 'blloor inmu.me 
response, seen in animals protected by immunoadjuvant therapy fran 
weakly immunogenic t.uro:rs like the Eir-4 lyitplana, suggests that this 
therapy m:xiel may serve as an effective system to assess other means 
of .iJmmmaoodulation which may lead to concomitant t.uror inummity. 
B. '!he Biology of Interleukin 1 
I!r-1 is a honnone-like protein which appears to play many roles 
in the inflanunatory am inmu.me :responses (64, 78). Table 1 briefly 
lists many of the wide range of attrib.Ites attributed to IIr-1, sane 
of which will be discussed in m:re detail later in this review. orig-
inal inuuunologic studies described I!r-1 as a soluble product :released 
fran activated macrcpmges (90) capable of co-mitogenic stiJra4ation 
of thyioocytes (89). HoiMver, I!rl has been redisoavered several 
times due to its nlll.tiple biological actiC11S. '!he original disoovery 
of such a host derived subst:aro! occurred in the late 1940S when 
fever was initiated by a soluble factor produced am :released by 
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activated peritoneal exudate cells, canprised predaninantly of neu-
troJ;hlls (20). 'Ibis substan:::e was called granulocyte pyrogen, am 
later erxiogenoos pyrogen (EP) , when it was fami that this substance 
accounted for the febrile associated with bacteria, erXiotoxin am 
IOOSt other exogenaJS pyrogeni.c materials (9,69). other tenns used to 
(MP) (298); B cell activaticm, differentiaticm am enharament of 
antil:xxly p:roducticm .in vitro by B cell activation factor (BA:F) (308), 
B cell differentiaticm factor (BDF) (118) or T cell replacirq factor 
Table 1. Actions attributed to 100110CY'te derived IIr 1. 
General process am target cells Activity 
Antituioor activity 
tuJOOr cells 
natural killer 
mac:rq;Xlages 
Growth arxi differentiaticm 
T cells 
B cells 
f ibrablasts 
Inflamma.ticm 
neutrqnils 
bone-mar.t'Olli release 
macrophages 
fibroblasts 
synovimn 
erdothelimn 
hepatocytes 
Tissue catabolism 
skeletal mscle 
osteoclasts 
c.homrocytes 
Central :nervous system 
hypothalamus 
unknown 
directly cytostatic arxi cytolytic 
augmentaticm of cytotoxicity 
enhanced lysis of tuioor targets 
lynpiokine production am release 
proliferation am differentiation 
proliferation 
chencl:axis, degranulaticm, 
FG release, ch.er!otaxis 
FG am collagenase release, growth 
ro am collagenase release 
FG release 
secretion of acute-P'lase reactants, 
control of plasma divalent cations 
proteolysis 
bone :resorption 
cartilage breakdown 
fever iniucticm 
sleep iniucticm 
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('IRFm) (119) I arr:i hel:per peak-1 (HP-1) (145) respectively. After 
nuch collaborative study of these Dn>kines, it became awarent that 
these activities arr:i associated acronyms were actually different 
biologic facets of a sirr;Jle biochemical family of m:>lecules. 'Ihere-
fo:re, IL-1 was introduced into the n:::manclature to elllninate con-
fUsicm arr:i distin:Jui.sh this m:mokine fran other inm.Jnoregulato:cy 
llX)lecules (1). 
1. 'lhe Biochemisb:y of IIrl 
'Ihe polypeptide nature of IL-1 was shown by enzymatic digestion 
with a variety of proteases (269) am loss of activity foll0t1irr:J 
arginine residue nOOification (206). 'Ihe possibility that IL-1 is a 
glycoprotein remains unresolved, although there is no direct evidenc.e 
that cai:Dohydrate :residues are present or essential for IL-1 bioac-
tivity (147 ,204) • Early estimates ~ the :nolecular weight of 
IIrl were often oonfusirr;J an:i oontradicto:cy. Part of this prct>lem 
arose fran the m:>lecu.lar weight het,en)geneity seen fran the intracel-
lular arr:i extracellular form of IL-1 (98) • All reports cannot be 
explained by this variatiai si.ral m:>lecillar weight species ran;iin;J 
fran 60 to 250 k:ilodaltons (kd) have been reported for both intracel-
lular arr:i extracellular foDllS of IL-1 (211,278,292). It is likely 
that these IL-1 species :represent either aggregates with contamin-
atin;J proteins or aC}'P:egates of the IIrl m:>namer resultin;J f~ mixed 
disulfide bridges between free cysteine :residues ( 64) • 'Ihe possibil-
ity of a high m:>lecular weight protein carrier for IL-1 may also 
explain these sporadic results; however, no evidence for such a car-
rier has been presented. several investigations have shown that IL-1 
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activity may reside in polypeptide cleavage products as small as 2 kd 
to 4 kd in size. A 4.2 kd peptide, which co-purified with PIF fran 
plasma of febrile human patients, exhibited biochemical dJaracter-
istics an:i bioactivity of IL-l (67). Also, IL-1-like peptides rarg-
il'Xl frail 2 to 4 kd have been fain:! in human urine which retain a 
port.ion of their bioactivity (142). '1hese reports may explain the 
~resistance of IL-1 bioactivity to certain proteases (204, 
269). Only after further purification an:i biochemical dJaracteriza-
tion can the relaticnship of these low DDlecular weight JOOlecules be 
oc:mpare to natural or recanbinant forms of IL-1. 
'lhe purification an:i biochemical dJaracterization of IL-1 has 
proven to be a difficult task. unlike many other circulatil'Xl hor-
m:mes, IL-1 is not stored in any glan:i or tissue; an:i when produced 
usil'Xl in yjj;;m superiniuction protocx>ls, only low piocm::>lar quanti-
ties are obtained (238). 'lhe production of large quantities of 
murine IL-1 by a phol:bol myristate acetate (IMA) stinulated, cloned 
macrophage cell line, P388Dl, (156) alle7Ned for its purification to 
haoogeneity (208) • '1he purified murine product dem:mstrated a JOOle-
cular weight of 14,000 an:i, as reported previously (84,210), exhib-
ited microcharge heterogeneity with isoelectric points (pI) of 4.9, 
5. o an:i 5 .1. More recent methods of IL-1 purification, utilizi!'Xl 
immunoaffinity procedures with a heterologous antiserum prepared in 
goats against murine IL-1 (207), have given a lll.1Ch higher yield of 
purified IL-1, thereby all~ JOOre detailed studies of the protein. 
Seven discrete species were isolated upon elect:rqiloresis of this 
material with each species havi!'Xl a different JOOlecular weight rarg-
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inq fran 13 to 17 kd as analyzed in a seoorrl dimension by sodium clo-
decyl sulfate polyac:rylamide electrqiloresis (SIS-PAGE) • 
Farly research characterizinq partially pirified human IL-1 
:reported a variety of mlecular weights generally in the 11, ooo to 
16,000 kilodaltai rarqe (27,157,292). High yield methods of produc-
tion of II.r-1 secreted fran human peri~ blood macrophages stimu-
lated with heat killed, formalin-fixed st:.ai;ilylococcus au:reus umer 
serum free oorxlitions allowed for the pirification to haoogeneity of 
human II.r-1 with a high yield of biological activity (149). Purified 
by ion excllan;Je chranatogra~y arrl affinity chramatogra~y on Procion 
Red agarose, the human IL-1, like its 11D.lrine CXJUllterpart, also exhib-
ited microdlarge het:ero;Jeneity with foor dla:tqed species havinq iso-
electric points rcm;Jinq fran 6. o to 4. 9. 'lhese values are sanewhat 
lower than that observed for human IL-1 by other investigators (153); 
however, these other reports analyzed sanples cxmt:ainirq other pro-
teins which may have influenced the iso-electric point for IL-1 by 
fonnirg cxmplexes (149). Analysis of the pirified human II.r-1 by two--
dimensional. electrcpioresis-electrof ocusinq qels dEm:>nstrated all 
foor charqed species have an identical :mlecular weight of awroxi-
ma.tely 17, 500. '!he presence of ail.y cna :mlecular 'Weight species in 
this preparation was prci>ably due to the serum-free culture oorxli-
tions. II.r-1 exhibits llllltiple apparent :mlecular weights in the 
presence of serum, lllOSt likely due to a reversible association with 
high mlecular weight serum carponents (244,292). Ccmplete amino 
acid analysis irrlicated an abumance of acidic residues in agreement 
with the low isoelectric point. No cysteine residues were fourxi, 
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which was not sw:pris.in; consider.in; IL-l activity is unaltered by 
reduc.in; agents. No gl11CX')S8Dline or galactosamine was foom. 'lhere-
fore, it is unlikely that IL-l is a glyooprotein (149). 
'!he t.remenb.ls poten::y of this protein has been denalstrated on 
the basis of PJrification data. Purified Dllrine IL-l, as dena1stra-
ted by Mizel (208) , has a specific activity of l x 106 U/llr;J protein. 
'Ihus, l U/ml Dllrine IL-l is equivalent to a D:>lar mx:ientration of 
7 x lo-ll M. Purified human IL-1 produced by D:>l'lOllUClear cells 
showed an even greater specific activity of 3.2 x 108 U/llg protein, 
with 1 U/ml of human IL-1 equivalent to a 1.8 x io-13 D:>lar concen-
tration ( 149) • 
IL-l mediates a diverse ran]e of biological activities, includ-
.in; stimulation of thyno::yte proliferation via in:luction of inter-
leukin 2 (IL-2) release (159,281), stinul.ation of B cell maturation 
arxi proliferation (97,118,259), augmentation of NK activity (61), 
fibroblast growth factor activity (268), iniuction of acute ~ 
reactants via stimulation of hepatocytes (287) , arxi stimulation of 
p:rostaglamin arxi oollagenase release fran synovial cells (206) as 
well as fever (261). 'lherefore, the question arises: can all these 
activities reside in a sirqle protein, or is there a family of inter-
leukin l's, each with separate or overlapp.in; functions? To clarify 
these issues, several D:>lecular biology laboratories have attenpted 
to clone the genes responsible for IL-l activity. 
2. '!be Molecular Biology of Interleukin 1 
Recently, several laboratories have isolated JDJrine arxi human 
carplementazy WAs ( cmAs) encodi.rg proteins with characteristic IL-l 
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activity. '!WO basic strategies have been utilized to screen macro-
};ilage ct.NA libraries in order to obtain cloned genes for which trans-
latioo products will encode for IL-1-like ioolecul.es. Macrqilage ct.NA 
clones were hybridized to macrophage RNA, arxi RNA isolate:l fran this 
process was injected into .in vitro translation systems with the 
resultant product assayed for IL-1 activity. 'Ihe seoom procedure 
utilized an oligonucleotide probe constructed on the basis of amino 
acid sequence analysis of highly p.n-ified human IL-1. 
'Ihe nucleotide sequences of the first two ct.NA clones codin;1 
for murine (167) or human (13) IOOnOcyte IL-1 code for polypeptide 
precursors of 269 arxi 270 amino acids respectively. 'Ihe preclicte:l 
primary translation products fran these clooes (inferred fran ct.NA 
sequence analysis) would yield proteins of 31,026 arxi 30, 747 daltons 
respectively. 'Ihis data stm:gly SUWorts earlier l«>rk identifyirg 
the production of a high JOOlecul.ar weight intracellular form of IL-1 
which was thought to be the precursor form of the 13, 000-11, ooo 
dalton mlecul.ar -weight IL-1 ioolecul.e isolate:l extracellularly (211, 
298). Al.thaigh the 33,000 dalton murine IL-1 was the predaninant 
intracellular form, arxi the 17,000-19,000 dalton IL-1, the predanin-
ant extracellular form; the 33, ooo ioolecul.ar -weight peptide was seen 
in the culture supernatant& imicatinj that IL-1 may be secreted as a 
33, ooo ioolecul.ar weight polypeptide arxi then rapidly converted to 
lowrer ioolecul.ar weight forms by macrqilage derived proteases (98). 
'lllis proteolytic activity may produce ragged amino termini, thereby 
p:covidirg a possible e>q:>lanation for the varied ioolecul.ar weights arxi 
microcharge heterogeneity often associate:l .with IL-1. 'Ihe human ctNA 
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II.r-1 clone isolated by Aural an:1 Dinarello (13), denalstrated a'lly a 
distant relatiooship with the :nardne IL-1 of Ianedioo an:1 Mizel (76). 
Al.though the relatiooship of these IL-1 molecules may be distant, 
there does exist a significant degree of sequence hcm:>logy an:1 struc-
tural similarities. Both of these :reoanbinant cmAs have sham the 
capability of producirg biologically active molecules dem::mstratin:J 
their furx:tional relatiooship (167,303). Protein sequence data irdi-
cate that these :reoanbinant forms of llllrine an:1 human IL-1 have amino 
termini beg~ at amino acid 115 am 117 respectively, gene:ratin:J 
IL-1 with a molecular size of 17,300 whose forms also oorrelate in 
terms of their net charge for each species. Amino acid sequence of 
the amino terminus am ~ cleavage fragments of the pI 6. 8 species 
of nonnal human IL-1 (36) conclusively shows that this species of 
IL-1 is coded for by the human crNA isolated by Auron §t .sY,. (11). 
'lherefore, it does appear that the IL-1 clones produced by Auron am 
Ianedioo oorresponi to forms of IL-1 c::ormonl.y desc::ribed in the liter-
ature. 'lhe absence of stron;J hcm:>logy between these molecules (11) 
suggests a possible explanation for the lack of antibody cross :reac-
tivity in spite of functional s.iltlilarity am species Wepemence 
observed in bioassays (65,138). Although antigenically distinct, 
these m:>lecules still presumably retain a CXllUOOll site required for T 
cell activation. 'lhe c-tenninal amino acids between residues-150-186 
in human am 161-197 in mrine IL-1 demonstrated the strcrgest regicm 
of hcm:>logy irdicatirg this region as a key to the functional role in 
IL-1 bioactivity. statistical evaluation of protein (59) irdicates 
these tw genes appear to be members of a nultigene family as q:p:>Sed 
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to beinj species counterparts (11). Recent collaborative "WOrk by 
nrm.mex am syntax corporations has shed :nx:>re light on these poten-
tial relationships. 'Ihey have obtained am sequenced two different 
human cWA IIr-1 clones, whose gene products they have referred to as 
IIrl ali;ila am IIrl beta (181). Al.t:hcuj'l this IIr-1 nomenclature is 
relatively new in the field, the al};ila am beta designations have 
became widely accepted terminology. Table 2 briefly sunnnarizes the 
characteristics of human IIr-1 ali;ila am beta. '!he human cWA IIr-1 
clone, isolated by Auror1 am Dinarello (13), was foun:i to be essen-
tially identical to the human IIr-1 beta produced by Immunex. Amino 
acid sequence oarparison of the I..anedioo reccmbinant mrine IIr-1 with 
human IIr-1 al};ila fran IllmJneX inlicates a close relationship between 
these two proteins which share sixty-two percent amim acid hcm:>logy. 
statistical analysis of sequence hanology inlicates Inm.mex's human 
IIrl alP1a is the lll.lrine IL-1 oountexpart (12). '!he first 39 N-ter-
minal amino acids sequenced fran an IL-l-like protein i;m-ified f:ran 
ooncanavalin A (Con A) stimulated human ll0'10cyte supernatants, havinJ 
a molecular 'Weight of ~tely l 7, ooo, sb::Ms extensive hcm:>logy 
to amino acids 117 to 155 of the cr:NA-derived human IIr-1 precursor 
sequence (300). All this data stron:]ly suggests that there are at 
least two genes c::odinJ for IIr 1. '1hese forms of II.r 1 appear to be 
distinct yet distantly related. 
Considerinj the possibility of nul.tiple genes producin] IIr-1, a 
major issue to be investigated in IIr-1 research is the rarxJe of 
biological activity associated with each of these gene products. 
Apparent differences in activity have been detected in the primary 
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translation products of IL-1 aliiJa am IL-1 beta; with IL-1 aliiJa 
de:nalstratin;J IL-1 activity, while umer similar ooniitioos, IL-1 
beta does not ( 181) • P.roducticn of large quantities of :recanbinant 
fo:rn& of IL-1, alQ'XJ with the producticn of Da10Clcnal antibodies 
specific for these different fonns, will allow the elucidation of the 
biological activities associated with each groop. 
Amino acid sequence analysis of IL-1 polypeptides has all~ 
carparison of IL-1 to several other lynpioki.nes with no sequence 
h.anologies seen with IL-2, IL-3, ganuna-interferon, am granulocyte-
macrq:hage oolony stimulatin;J factor (11). 
3. sources am Production of IL-1 
Cells of the m::>noeyt:ejmacrq:haqe lineage were first thc:u;1ht to 
be the sole source of IL-1. M:>st tissue sources oontainin] na'lO'-
nuclear piagocytes, includin;J peri:r;ileral blood m::>n0cytes (90,91) I 
alveolar mac:cq;tlages (10,278), hepatic RUpffer's cells (66), splenic 
macrq:hages (10), peritoneal macrqilages (136,216), bone marrow 
Table 2. craracteristics of human :recanbinant IL-1 aliiJa am beta. 
craracteristic IL-1 alliJa IL-1 beta 
Major secreted species by No Yes 
stimulated ma~ge 
PrimaJ:Y translaticn 30,606 30,749 
product MW ( daltons) 
Final cleavage product 18,063 17,377 
MW (daltons) 
!so-electric point (pI) 4.9 - 5.3 6.8 - 7.2 
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adherent cells (160), an:i placental lla'lOJ11Clear pmgocytes (87), have 
been shatm to produce IL-1 usirg either the emogenous pyrogen or IAF 
assays. '!he production of IL-1 has also been associated with myelo-
ioonocytic cell types, such as P388Dl, J774, U937 am 'IHPl (237). 
other cell types of non-macrqbaqe lineage also produce IL-1 in 
response to a wide variety of still'llli. '1hese non-macrqilage cells 
include epithelial cells of the skin, epidermal keratinocytes, (171, 
172,173,264), arxi cornea (104), glia arxi gliana cells (88), glaner-
ular mesarqial cells (169), girgival exudate cells (45), I.arqer.hans' 
cells (64), lymphci>lastoid B cell lines (6), stimulated B cells 
(267) / large granular l}'lllilocytes (IGL) (266) / fibrd>lasts (127) / 
an:i, mst sw:prisirgly, polYJID:qilalllclear cells (FMNs) (218,318). 
'!he strateqic location ard wide distribltion of IL-1 producirq cells 
supports the ocn:::ept that this soluble mediator is clirectly involved 
in host defense mechanisms ( 64) • 
Initial sbxlies ( 158) Sl¥J9eSted that IL-1 was produced in rl.Y"Q 
without still'lllation. However, it was fami that the macrqhages 
umer study wre still'lllated by picogram per milliliter levels of 
erdotoxin, wch is bela.r.r the limit of detection by the limulus 
lysate test, but often fourxi oontaminatirg laboratory materials (9). 
Use of the cationic antibiotic polymyxin B easily rules rut contam-
ination by negatively charged lipid A oontaini.rq erdotoxin JIDlecules 
without inpairirg cell function (58,72,256). 
'!he.re is a wide variety of agents capable of imucirg IL-1 
production by llD1'l01'1Uclear };ilagocytes. Jtt:ist of these agents are pyro-
genic, producirg fever in humans am experimental animals ( 69) • Aside 
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fran gram-negative bacterial endotoxin, other microbes, microbial 
fractions or microbial by-products such as gram-p:>sitive bacteria 
(cell walls, mmmiyl dipeptide, exotoxins), yeast cell walls (zyno-
san), sp:irodletes (35) arxi viruses may also irXluce !Ir-1 production. 
A 20 to 30 kd toxin produced by sta'Q:lylococcus aureus, isolated frau 
patients with toxic shock symrane, has been shown to be equal in 
potency to gram-negative eniotoxin in its ability to imuoe produc-
tion of IIr-1 in vitro am JD vivo (126) • Inflammato:ry agents such as 
bile salts, etiocholanolone, urate or silica c:i:ystals (73), csa, arxi 
antigen antibody oanplexes fonoed in antigenic excess, also irXluce 
IIr-1 production JD vitro (74). Various plant lectins, such as Iityto-
hemagglutinin (mA) am con A (22,241), am antigens (44) includin;J 
alloantigens (63), irduce !Ir-1 stimulation via lynphaki.nes. Macro-
phages activated with colony stimulatin;J factors have also been shown 
to respord by increasin;J !Ir-1 production (213). 
It is generally thought that surface receptors are involved in 
the stimulation of };ilagocytes to prcxiuce !Ir-1 (78) • It bec:aoos 
apparent that stimulation 1Illst occur at the macrqilage membrane since 
blocld.rq of phagocytic uptake of spirochetes (35) or urate crystals 
(73) by cytochalasin B or colchicine does r¥Jt inhibit IIr-1 stiirllla-
tion. serum am oanplement ccup:nmts are also thought to play a 
role in the eventual production of !Ir-1 by activated macrqilages. 
Although r¥Jt required, serum enhances the sti.nulation of IIr-1 pro-
duction in vitro by erdotaxin arxi staii}yloooccus midermidis (154). 
'!be p:>sSible relationship of serum enhaix::ed !Ir-1 production may be 
explained by recent firxlin';1s that macrqilages have receptors for the 
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anaphylatoxin, csa, on their surface (46), arxi that pn-ified human 
esa will imuce macrqilage IL-1 production (99). 'lhe Ia (I region-
associated) or HIA-I:R (human leukocyte antigen DR) glycoproteins on 
the surfaces of macrophages have also been inplicated in the activ-
ation process leadin;J to IL-1 prcx:luction. '1hese surface markers, 
believed to participate in antigen activation of T cells which bear 
receptors for Ia (260,297), may perfo:nn a receptor-like role on the 
surface of macrophages. Several reports have deloonstrated that T 
cells imuce IL-1 :release fran macrophages via an Ia-:restricted 
interaction (76) arxi that anti-Ia mnocla1al. antibodies inhibited 
both T cell arxi I.PS imlCed IL-1 production (77 ,96). Incubation of 
mnonucl.ear pmgocytes in nonstinulatirg culture ocnlitions for 24-48 
boors results in the loss of Ia surface markers oo these cells. 
Associated with this loss of Ia surface antigens is the ability to 
:fun:::tion as aooessoey cells for antigen processin;J arXl produce IL-1 
in response to I.PS (54) • Treatment of these cultured cells with 
i.rnanethacin prevents the loss of both Ia expression arxi IL-1 pro-
ducin; capability (284). '1hese observations stron;ly suggest that Ia 
receives stimuli culmina~ in the release of IL-1. 
It should be noted that not all macrqilage stimulators in:iuce 
IL-1 production. Isvamisole, tuftsin, arxi Naio4, which perturt> cell 
membranes, cause superoxide aniai generation arxi activate other known 
macrophage furx:tions, do not stimulate IL-1 production by human 
macrophages (154) • A smprisin;J result of amino acid analyses of 
reccmbinant IL-1 is the lack of a classic signal peptide (13,167,181) 
which directs newly synthesized proteins to their ultimate destin-
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ation, whether in or out of the cell (26). 'Ihis result leaves open 
the lorg-st:ardin;J questicn of how IL-1 is excreted fran the macro-
~am other cell types. 'lhe fin:linJ of a slightly hyarc:plabic 
region of seventeen residues at the amino terminus of both llllrine 
(167) am human (13) IL-1 may represent a functicmal. danain involved 
in transport (11), altha.lgh this region bears little resemblazx::e to 
signal sequences foun:l in other secreted proteins leadin:j to the 
previously described inefficient secretion of the protein (91) • 
Dinarello has postulated that the suicidal nature of macrq;ilages 
involved in their fight against infection may lead to the release of 
IL-1 (182) • 'Ihis type of mass release may be inportant in the 
infla:nunato:cy process ( 64) • other investigators have identified 
surface membrane associated IL-1 with potent thyioocyt:e am T cell 
stillW.ato:cy activity on demritic cells (217), fixed macrq;ilage mno-
laye:rs, am an membranes isolated fran unfixed macrq;ilages (151). 
Membrane IL-1 appears to be an integrated membrane protein since it 
was solubilized by detergent, but not eluted by (Ethylenedinitrilo)-
tetraacetic acid (EDI'A), high salt, or 10"1 l=fl treatment of the mem-
branes. 'Ihis report Wicates that previous "Werk dena1Stratin] IL-1 
imepen:ient T cell lines (21) are not imepenient of IL-1, but rather 
that fixed macrqi1ages have sufficient IL-1 en their surfaces to sup-
port T cell proliferation withalt the adlitian of soluble IL-1. 'lhe 
authors suggest that iniucticn of membrane IL-1 may focus the activ-
ation signal to T cells biJXlirg to the macrqilage via their antigen 
receptors (151). 'Ihis 'WQJld obviously all0"1 for the enharx::ement of 
the inm.me response wit:hoot the necessity of mass mac:rqi'lage lysis. 
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4. Inununologic Activity of IL-1 
'lhe ability of cells to reswm to IL-1 ai;:pears to work via 
specific membrane receptors similar to that described for other hor-
IIVJileS (71). Workers at Illl1amex have shown that human 125I-IL-l bi.ms 
specifically to cells of lyJ!liloid or fibroblast/epithelial origin; 
cells on which IL-1 is kIXMll to have a biological effect (71). IL-1 
was fooni to bil'Xi with high affinity, am to associate with a mem-
brane protein of 80, ooo 100lecular weight, suggestirq a specific mem-
brane bourd receptor for the protein. 
'!here are a wide variety of inm.mologic actialS DKXiulated by 
IL-1 which may be shown to be inport::ant in tunDr i.nm.mity. '!he abil-
ity of IL-1 to be mitogenic for t.h.yD:>cytes (89) was the earliest 
recognized effect of IL-1 on the inm.me system. It remains as the 
reference assay for IL-1. 'lhe ilrportanoe of this lynphokine in T 
cell activation is demnstrated by the ability of IL-1 to restore 
antigen or mitogen .in:iuced T cell activation when antigen presentin:J 
cells are reiooved fran the culture pop.llation by P"iysical means (281) 
or by use of anti-Ia treatment (76,159), SU39estin; that IL-1 is a 
required CCl'lp)Ilellt leadinJ to expansion of T cell pc:p.1latiais. IL-1 
has been shown to sti.Jllll.ate the production of interleukin 2 (IL-2) in 
both murine am human systems (178,254). 'lhus, it has been prcposed 
that IL-1 stinulates antigen or lectin activated T cells allc:M~ the 
cells in the Go rest~ state to enter the G1 stage of the cell 
cycle, result~ in the release of IIr-2 by these cells (159,281). 
Antigen activated T l~ bear~ IL-2 receptors are in tum 
.in:iuced by IL-2 to enter the S P1ase of the cell cycle ( 53) • In 
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several reports it has been shalln that adjuvant active peptidoglycans 
can in:luce IIr-1 productiai by lll.lrine arxi human naxmuclear cells 
(128,242,299,310). IIr-1 has deloonstrated similar imm.moenhaooirg 
activity for defined antigenic systems in vivo, suggestirq that IIr-1 
may be a oc:rnnv:>n m:xie of actiai of immunological adjuvants (285,312). 
'lhe ability of IIr-1 to up-regulate the immune :response is mre clear-
ly seen by INt antigen ~ic analysis of T cells (31, 38) :re-
spordin;J to IIr-1. IIr-1 ~ to prarote the generation of INt l+ 
helper cells in vitro arxi inhibit the generation of INt 2+ suppressor 
cells (78) • 'lhe INt 1 + T helper cells secret IIr-2 in response to 
IIr-1 (140), augmentirg the generation of cytotoxic T cells (84,276, 
301). Antilxxlies directed against helper T cells which blook IIr-1 
:flmction, prevent the production of IIr-2 by helper T cells, but also 
prevent the generation of cytotoxic T cells, strorgly suggestirg that 
IIr-1 stin'All.ation of cytotoxic T cells awears to :flmction via its 
ability to imuoe IIr-2 (193). 'lhe conversion of the macrqilage de-
rived maturational signal, IIr-1, into a secxn:lary T cell derived pro-
liferative signal, IIr-2, results in the anplificatiai of an antigen 
specific immune response. Aoother soluble macrqilage factor, ini-
tially described as BAF, was shown to increase levels of antibody to 
sheep red blood cells released fran splenocytes of nude mice (309, 
311) • 'Ibis factor was later identified as IIr-1 when it co-purified 
with IAF (308) , arxi its activities were inhibited with antil:xxiles 
against IIr-1 ( 166) • continued reseal:dl has shown that B cells are 
reactive to IIr-1 durirg at least two stages in their develcpnent. 
Farly stage B cell maturational control was initially reported by 
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Hoffmann et al. , (118) who described a macrophage factor irrlucin;J 
maturation in pre-B cells. 'Ihis factor was verified as IL-1 when 
:p.Irified IL-1 st.llrulated ka:rpa light-chain production and subsequent 
expression of membrane immunoglcbll.in (Ig) in pre-B cells (97). IL-1 
has also been shown to synergize with suboptimal c::a"Dll1trations of 
anti-ni chain, .llxlucin;J B cell pmliferaticn and terminal. differ:en-
tiatioo (82) • '!be capacity of antibodies against IL-1 to abrogate 
this in~ antibody synthesis (166) I straqly Wicates that IJrl 
may be critical for B oell activatioo l~ to antibody production. 
IL-1 activation appears to be required xelatively early (within 
twenty-four hours) after B oell stinulation by antigen or anti-
immunoglab.llin (117) as are other early actin;J cytakines such as B 
cell growth factor (aa;F) (124) and possibly IL-2 (161) ~ch drive B 
cells thra1gh mitosis. Followin;J early B oell activatioo, late 
actin;J lYJlPlo]dnes such as ganmia-int.erferon (277 ,320) lead to further 
B cell differentiation and production of antibody. '1he source of 
IL-1 needed for B oell activation and differentiation was assunm to 
be the activated macrophage. HoWeve.r, recent in vitro sbnies inli-
cate that B cells may play the role of accessoey cells (8,47,191) in 
the absence of ma.crqilages. '1he absence of I~l-like activity in B 
cell culture super.natants produced an apparent paradox sin=e there 
appeared to be no souroe of IL-1 available to T cells in these sys-
teins. '!he fi.rxlin;J of surface membrane IL-1 on ma.crqilages (151) 
leads to the resolve of this prci:>lem when the same investigators 
determined that B cells could be irxluoed to express membrane IL-1 
only when st.llrulated with both anti-immunoglab.llin and T oell lyq:ho-
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kines ( 152) • In contrast to B cells, macrqilage exp:ression of IL-1 
is not deperrlent on T cells or their products ( 151) • 'lhe awearanoe 
of an IL-1 inhibitor, produced by an Epstein-Barr virus-transformed 
hUman B cell line (267), may acxnmt for lack of IL-1 activity in B 
cell supernatants (6,267) am the necessity of cell to cell contact 
between accessory B cells am responiln:J T cells. 'lhe differences in 
the stimuli needed to irxiuce membrane IL-1 on the surfaces of B cells 
ard macrqilages suggests that these antigen presentinq cells may 
serve diverse roles in the i.rduction am maintenance of the inm.me 
response (152) • Also, the apparent lack of a signal peptide in the 
precursor fonns of reoanbinant IL-1 isolated to date suggests that 
the membrane form of IL-1 may be derived fran a different family of 
genes than those associated with the soluble form of IL-1. 
Another cell in the inm.me system which responjs to IL-1 is the 
macrqilage. IL-1 is a chem::>a.ttractant for these cells (170,265), it 
in:iuces the release of prcstaglardin E2 (~) (68) , ard is involved 
in activation for tunm'-oell killinq (240) • Prostaglardins have been 
inplicated to have inhibitory effects ai macrq:ilage productiai of 
IL-1 (78). Whether this is a case of autoregul.atiai with the same 
macrqi1age cell producirq IL-1 responiln:J to its release by producinq 
am releasin;J ~has yet to be determined. 
5. other Biologic Activities of IL-1 
'lhe ability of a host derived soluble proteinaceous factor to 
irxiuce fwer associated with m:>st, if not all, pyrogenic substances 
(6,69) initiated :researdl into EP. 'Ibis protein appears to regulate 
body tenperature by raisin;J the hypothalmic setpoint as a function of 
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EP's ability to increase levels of prostaglamins in the brain arxi 
oerebra1 spinal fluid (23,50). As the methodology of protein chem-
ists inproved allowirq the separatiai arxi examinatiai of partially 
purified factors which augment a variety of p:iysiologic responses 
includirq fever arxi the acut:e-pmse response, it becaJie apparent that 
these biological activities 'lim'e biochemically inseparable (131). 
'lhe fi.rxiin; that EP arxi IAF activities were also biochemically 
inseparable in several different animal species (216, 261) , catalyzed 
the developnent a broad oorrept li.nkirg the host febrile response to 
inm.moregulatiai. 
It has :been well established .that the acute response to infec-
tious diseases arxi pyrogenic substmxles prcxiuoes neutJ:q:bilia in 
associatiai with fever (56). '!he neutrqililic response generated by 
IL-1 seems due to the accelerated release of mature neut:rophils from 
the bone marrow reserves, as there is a severe loss of mature neutro-
phils in the marrow followirq injection with EP (134). IL-1 has also 
:been observed to dramatically increase the synthesis of acute phase 
reactants, a group of proteins produced by the liver in response to 
infectiai or inflammatiai {196,287). '!hose acute phase :reactants 
normally present in the plasma; sudl as serum amyloid A (187), fib-
rinogen (133), haptoglabin (120,133), arxi ceruloplasmin; generally 
increase several fold when the host is stinul.ated with IL-1. . '!hose 
proteins normally seen in the plasma at extremely low concentrations, 
such as c-:reactive protein, rise several hurxh'ed fold in response to 
IL-1 (195,293). Whether IL-1 is actirq alone or together with other 
factors in the iniuctiai of these acute phase :reactants is still tm-
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clear (64) • 'lhe accelerated synthesis of ceruloplasmin by IL-1 (131) 
acoamts for the increase in the plasma level of oog>er ions, gener-
ally considered vital to oanbat bacterial diseases (251) • TlNo other 
plasma divalent cations (ziro am irm), affected by the presence of 
IL-1, show a rapid drcp in plasma concentration (132). IL-1 imuced 
neut.rqnil. degramll.ation leadin;J to the release of lactoferrin (144) 
leads to the rapid drcp in irm levels am is a major host defence 
mechanism against microbial infection. IL-1 has also been ilrplicated 
in the regulation of tissue catabolism durirq infection or trauma 
when the host must Dd:>ilize a variety of oc:qx>nents needed for syn-
thesis or energy by irducirq nuscle tissue proteolysis (14,49), bone 
resoi:ption by osteoclasts ( 102) , an:l cartilage breakdown associated 
with oollagenase am proteoglycanase production by human chomrocytes 
(103). 
6. Potential Antituioor Activities of Interleukin 1 
'!he many biologic activities of IL-1 diSOJSsed above, both in 
the nature of inm.moregulation an:l piysiologic regulation, demon-
strate the potential use:fUlness of this 1la10kine as an in vivo thera-
peutic agent. '!he activated macrqilaqe is t:houJht to play an inport-
ant role in host defense against malignant neoplasia by exertin;J a 
cytotoxic effect an tunm' cells (85) • IL-1 has been shown to prcm:>te 
human llalOcyte-mediated tunm' cytotoxicity possibly by prolon;Jirq the 
cytotoxic state of :ironocytes (235) • Macrq:hage cytotoxic effects are 
thought to be mediated by several possible effector ioolecules includ-
irq lysosanal enzymes (116), oxygen intennediates (221), arginase 
(55), a neutral p:roteinase (2), an:l tuioor necrosis factor (180,319). 
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Purification of human IL-1 (185) has allowe:i Onozaki et al. to de.nal-
strate the direct cytocidal am growth inhibitory capability of IIr-1 
against a human melanana oell line ID Yi1;;rQ (236). 'lhus aail.n:] IIr-1 
to the list of potential macrophage cytotoxic mediators. Human JOC>l'lO-
cyte derive:l IIr-1 has been shown to augment the activity of highly 
p.irified human IGL or NK cells which are cytotoxic to a variety of 
malignant cells (141,225) am have been inplicated as inp:>rtant medi-
ators in the prevention of tuJoor development am metastasis (110, 
137). Augmentation of this activity inplies a possible role for IL-1 
in inm.me surveillance of spcmtaneaJs or metastatic tuJoors (186). 
'Ihe previously discussed ability of IIr-1 to augment the inm.me re-
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sponse to specific antigens ID vivo (285,312) allaws speculation that 
IIr-1 may be able to save an immunoadjuvant for tun¥:>r associated 
antigens. Several inp:>rtant observations can rt:N be made f:ran ele-
ments discussed in this revie'ft'. First, it lNOUl.d appear that C. 
parvum may act as an immunoadjuvant in the C57Bl/6:EI.r-4 tun¥:>r lOOdel 
by enhancin:J macrophage fuootion. 5ecorxlly, the m:xlulatory ftuttions 
of IL-1 have been shown to nv:>st likely act via lyqhocytic pcp.ila-
tions. 'Iherefore, by oanbinin:J the protective c. parvum therapy with 
systemic IL-1 administration, this study set out to detennine if IL-1 
could IOOdulate a protective iimnune response to the nonimmunogenic 
EL-4 lymphana. 'Ihe effects IIr-1 may have on the involved lyn'Plocytic 
populations will allOW' suggestions as to possible ne::-.hanisms which 
might lead to the development of b.uoor immunity in this system. 
CliAPl'ER III 
A. '!he Mice 
CS7Bl/6 female mice, ages seven to twelve weeks cbtained fran 
Jackson Iaborato:cy, Bar Harbor, ME, were used for all IL-1 in vivo 
tum:>r protection studies. Similarly sexed arxl aged C57Bl/6 mice 
obtained fran Olarles River Breedin.1 Iaboratories, Inc., Boston, MA, 
arxl Iab SUR;>ly, Plainfield, IN, were utilized for macrqilage activa-
tion studies. Lynploid tissues fran DBA,12J arxl CJ:fVHeJ mice, aged 
seven to sixteen weeks (Jackson Iaboratory), were used for IL-1 
assessments. 
B. '!he Bacteria 
'!he Coeynebacteritnn parvum strain 4182 (Propionibacteritnn 
acnes) was been obtained fran the Pasteur Institute, Paris, France, 
arxl periodically identified by API 20 Anaerobic System (Analytab 
Products, Plainview, NY) (212,283) arxl metabolic em-products deter-
mination by gas-liquid chranatograpiy (214). '!he bacteria were grown 
anaerobically in liquid culture usirg Brewer's thioglycolate neiltnn 
with inlicator (Difeo Iaboratories, Detroit, MI). Ten milliliter 
starter cultures were incubated at 370c for five days, then trans-
ferred to one liter thioglycolate broth cultures. '!he cultures 
remained at 370c for seven days urxier anaerobic corxlitions with 
occasional agitation. '!he organisms were haJ:vested with the Beckman 
TJ-6R centrifuge (Beckman Instruments, Inc., Palo Alto, CA) at 1500 x 
31 
gravity (g) for twenty mimtes, am washed five times with sterile 
saline. 'lhe organisms were heat-killed at sooC for thirty minutes 
with inspissation, aliquoted at 2 x 109 cells per ml am stored at 
-2ooC until needed. 
c. 'lhe Turoc>r Cell Lines 
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'lhe EI.r-4 lynphana, a 7,12 diamethylbenz(a)-ant.hraoene in:luoed 
turoor, was originated in 1945 by Gorer fran C57Bl/6 mice. 'lhe Eir-4 
lynphana has been shown to be a tumr of lCM illm.nx>genicity (39,100), 
am nonsusoeptible to NK lysis (114). 'Ibis tumr was C'btained fl:an 
Dr. R. Hetioennan, Iaboratory of Inm.modiagncsis, Naticntl Qm:ler 
Institute, Bethesda, MD. 
'lhe RBL-5 lynphana, also obtained fl:an Dr. Hel::beman, is a 
Rausher mrine virus-irxi11Ced lynphana (189), am like Eir-4, is syn-
geneic in the C57Bl/6 DD.JSe. 
'lhe YAC-1 lyqtiana is a Molooey mrine virus-irxi11Ced lynphana 
(280) which has been shown to be susceptible to NK lysis (114,141). 
'lhe EI.r-4 ascites bmm" banks were maintained .in YiYQ by I i. P• I 
passage. A 0.1 ml suspension of EI.r-4 ascites cells in Hank's bal-
anced salt solution (HOOS) at 1 x 107 cells/ml was injected, i.p., 
into syn;ie.neic C57Bl/6 mice, typically at ten day intervals. EI.r-4, 
RBL-5, am YAC-1 cell lines were maintained in ~ by grcM:l1 in 
suspension cultures in RIMI-1640 culture medimn (Grani Islarxi. Bio-
logical C'alpany, Gram Islam, NY) (GIBCX:>) , Iii 1 .1 to 1. 3, suwle-
mented with five or ten pel'Oel'lt fetal bovine serum (~) (heat in-
activated at 56oC for ale hour) (GIBCX:>) 100 units/ml potassimn peni-
cillin G, 100 ug/m1 streptanycin (sulfate), 2.5 ug/m1 fun:}izone 
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(Whittaker M. A. Bioproducts, wal.kersville, MD) arxi 2 JIM L-glutamine 
(Whittaker M. A. Bioproducts). All .in vitro cell cultures utilized 
for experimentation or propagation in this study were maintained at 
370c with five percent a:>-i in high humidity, unless otherwise state;i. 
Media supplemented with L-glutamine arxi the antibiotics listed above 
will be :referred to as oarplete medium. All routinely in vitro 
passaged cell lines were incubate;i in either 50 ml or 500 ml tissue 
culture flasks (COmin;J Glass Works, comin;J, NY). 
'!he P388Dl maaqi1age-like cell line, A'n::C-TIB-63, (American 
Type CUl.ture COllection, 'l\Jm:>r Ilmmmology Bank, Rockville, MD) was 
derived fran a methylc:holanthrene-imuced lYJlPioid neoplasm (P388) of 
a DBA/2 m:iuse (57). It has been utilized consistently as a source of 
erxiotoxin iniuced ImJrine IL-1 (155,205). '!his cell line has been 
shCMil to retain many maaqi1aqe cell-like properties includirq the 
ability to ~gocytize latex particles arxi zyioosan, firmly adhere to 
glass arxi latex, arxi carry cell bourrl receptors for immunoqlcbllin 
(Fe) arxi catplement (C3) (146). '!his cell line has no detectable 
surface inum.moqlcbllin (146) , exhibits high effector activity in an 
antibody-deperxient cell mediate cytot:a>d.C system (252) I arxi synthes-
izes lysozyme (253). '!his cell line was maintained .in~ as mno-
layer cultures in oarplete RFMI-1640 mdium supplanented with ten 
percent FaS. A secorXl P388Dl cell line, obtained fran Dr. Y. _Yama-
mura (Ponce SC.hool of Medicine, Ponce, Puerto Rioo) , was a clam 
cell line which oonstitutively produces IL-1 (317). '!his cell line 
was derived by Dr. Yamanu.Jra fran a cell line isolate;i by Dr. H. Koren 
(D.lke University Medical center, Dlrtlam, NC). '!his cell line was 
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maintained in vitro in catpl.ete m-alJila medium without rucleosides 
(Grard Islarx:i Biological Catpany, Grarx:i Islarx:i, NY) supplemented with 
seven percent FBS. To avoid OCllfusion, the cell lines d:Jtained fran 
the American Type CUlture a:>llecticn (A'ICC) arx:i Dr. Y. Yammmira will 
be referred to as P388DlA arx:i P388DlY respectively. 
D. IL-1 Production by P388Dl Macrqibage cell Lines 
IL-1 required for in vivo experimentation was produced usirq 
the constitutive IL-1 generatin:J PJSSDlY cell line as previously 
described (317). PJSSDlY adherent cells were nm:wed frail statiaw:y 
DalOlayer cultures with a rubber policeman or by rigorous pipett.irg. 
'!he cells were pelleted by oentrifugatioo at 400 x q for seven to ten 
mimtes, washed once in HSSS, ani then seeded in 50 ml tissue culture 
flasks at 2 x io5 cells/ml in 10 ml of oarpleta m-al.Jila medium with-
out nucleosides plus five percent emotoxin-free FBS (HyClone IaOOr-
atories :m::. , I.ogan, ur) • After three to five days of incubation, 
the culture supernatants were harvested by decantation, then centri-
fuged an:vor filter sterilized by passaqe through a 0.45 um SWinnex 
filter unit (Millipore Q)l:p., Bedford, MA) to renxJVe aey remainin;;J 
cells. '!be IL-1 oontaini.n;1 ocnlitioned medium was aliquoted am 
frozen at -200c tmtil required for experimentation or assay. IL-1 
has been shc7tln to remain stable for at least six lOOllt:hs umer these 
c:x:>niitions (205). 
P388DlA cells utilized. for product.ion of IL-l were prepared 
for seedinq in the same manner as described for the PJSSDlY cells. 
Production cultures were seeded at 2 x 105 cellsjmljwell in 24-well 
tissue culture plates (Falcon Plastics, Ios ~eles, CA) • eel.ls were 
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incubated either with or without 10 uq/m1 lipopolysaocharide (LPS) B 
frail sal.npnella tygiosa 0901, (Difeo, Detroit, MI) for three days. 
'!he c:W.ture supernatants were harvested, aliquoted, ard stored as 
described above for P388DlY supernatants. caxlitioned supernatants 
fran macrqilage c:W.tures not qiven LPS were utilized in the in vivo 
protection experiments as control macrqi'laqe comi.tioned mcUa. 
E. Recombinant II.r-1 
Purified recanbinant murine IL-1, derived fran a cloned murine 
cmA qene for IL-1 in F.scherichia coli (167), was generously supplied 
by Peter T. I.anedioo (Hoff'mann-IaRoc:he In::. , Nutley, NJ) • '!his pre-
paration of IL-1 had an activity of 4 x 106 units/ml am was main-
tained in SM Guanidine hyOroc::hloric acid (HCl) buffer. '!he recanbi-
nant IL-1 sanple was diluted to the concentration desired for assay-
i.rg or for in vivo experimentation in HBSS containin;J 250ng/ml. human 
serum albumin (HSA) as a carrier protein. '1he diluted IL-1 was then 
aliquoted am stored at -2oOc until needed. similarly prepared HSA 
sol.utia1S (250ng/ml) withcut IIrl were aliquoted am stored at -200c 
am used as control injectiai mixtures for the nurine recanbinant 
IL-1 .in vivo protection experiments. 
F. llr-1 Assays 
'!he starxiard co-mitogenic thyioocyte assay was utilized to 
assess llr-1 activity as previoosly described by Mizel (209) • _'!he 
thynDJS from either a C3JVHeJ or DBA/2J JOC1USe was aseptically :ren¥JVed 
followin] cervical dislocation of the animal. A si.rgle cell suspen-
sion was prepared by passaqe of the tissue thrcu3h a 60-mesh wire 
screen into HBSS. '!he suspension was decanted into a 15 ml conical 
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centrifuge tube (COmin;J Glass Works I comin;J I NY) where large cell 
cl'UllpS were allowed to settle for five minutes before the cell sus-
pension was again carefully decanted to another tube. 'Iha cells were 
washed once in HBSS, resuspeMed to l x 10 7 cells/ml in oaiplete 
RIMI-1640 medium, am plated at 100 uljwell in 96-mi.crowell. tissue 
culture plates (Microtest III, Falcon Plastics, IDS ArYJe].es, CA). 
'!he culture medium was supplanent:ed with FBS, piyt:dlemagglutinin P 
(mA-P) (Difeo, Detroit, MI), am 2 mercaptoethanol (2-ME) (Sigma 
Cllemical co., st. I.alls, H:>); such that a final ocaoentration of ten 
percent FBS, o. 01 percent mA-P am 5 x io-5 M 2-ME was attained when 
final volumes were added to each well. Varyin;J am::mits of test sam-
ples, rangin;J fran O ul to 50 ul, were added to each well with an 
awropriate ano.mt of culture medium added brinqinq each well to a 
200 ul total volume. All sanples ard controls were tested in tripli-
cate. Follc::Min;J sixty-six hours of incubation, the microcultures 
were PJ].sed with l uCi 3a-thymidine (7. 6 Ci/ltm:>le) , l nCi in 20 ml 
HBSS (ICN Bianedicals, Inc., Irvine, CA). After an additional six 
hours of incubatial, the microcultures were harvested onto glass 
fiber filters (cambria;Je Techoology, Inc., cambridge, MA) usin;J a PHO 
autanated cell harvester (cani>ridge Technology Inc.) • '!he degree of 
radiolabel inco:i:poration for each sanple was deter.mined usinq liquid 
scintillation ~ {Unilux II, Nuclear-aiicago, I;les-
Plains, IL; or IS580l, Bedmlan Instruments, Irvine, CA). 
A variatioo of the stamard IIrl assay described by Yamamura 
(317) , utilizinj murine splenocytes, was also incorporated into the 
study. Splenocyte cell suspensions were obtained fran IB\/2.1 mice in 
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a similar manner as described aba\Te for the thyioocyte assay. Eryth-
rocytes in the spleen cell suspension were destroye:i by rapid hypo-
tonic lysis with distilled water. 'lhe rema:i.nirg white blood cells 
were washed twice with HBSS, and resusperxied in c:xmplete m-alpha 
medil.ml supplemented with 0.01 percent mA-P. No FBS or 2-ME were 
included in the incubation mdia. For this assay cells were resus-
penied to 2 x 106 cells/ml before platirx] 100 uljwell of the splen-
ocyte suspension into inlividual wells of a 96-microwel.l plate. Test 
sall'ples and medil.ml were added to the wells as in the thyioocyte assay. 
'Ihese microcultures iooubated for forty-eight hours followed by a 
twenty-four hour p.ilse with 3a-thymidine. Harvesting and radiolabel 
countirg procedures for the splenocyte assay were the same as those 
described for the thyioocyte assay. 
Units of IL-1 were aJ:bitrarily determined by equatirx] aie unit 
with the capability of stilmJlatirX] thyn¥:>Cytes or splenocytes to aie-
half the maximal value obtained in the assay with a high activity 
P388DlY supernatant :refere?D! lot of IL-1. 
G. In Vivo 'l'Ullm' Protectial smiles 
CS7Bl/6 mice were chal.len;Jed intradennally (i.d.) on the right 
flank with a 0.1 ml suspension of EI.r-4 t.uioor cells susperded in HBSS. 
'Ihe tull¥)r dose rarqed fran 1 x 103 to 5 x 103 cells per injection. 
'Ihe EI.r-4 ascites cells had been previously rerooved fran the periton-
eal cavity of a m.:irine tull¥)r bank, washed once in HBSS, and prarptly 
injected in the mice either alaie or as an admixture with 2 x 109 
heat-killed c. paryum bacterial cells. 'Ihe c. parvum suspension had 
been lightly sonicated after :rem:wal fran freezer storage to elf.mi-
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nate bacterial clunpirq before admixture with the tmoor cells. As 
previously described (121) , animals receivirq both tmoor challen;ie 
protocols were divided into two groups. one groop fran each protocol 
was given m further treatment. '1he secxni groop of animals fran 
each protocol was given aoxmpanyirq systemic IL-1 therapy. Animals 
reoeivirq IL-1 therapy (either IL-1 cxmt:ainin;J oon:li.ticmed culture 
supernatants obtained fran the P38801Y CXllStitutive IL-1 produc::irq 
cell line, llB.lrine :recanbi.nant II.r-1 or U>S irrluced P388DlA cell line 
oorditioned culture supernatants) were administered equal unit dos-
ages of IL-1, i.p., everyday or ai alteJ:.nate days startirq with the 
day of tUloor challen:ie am eniirq nine days later. cantrol animals 
received aooanpanyirq systemic therapy (in the fom of either P388DlA 
oon:li.tioned culture supernatants or a 250 ng/ml. HSA solution) usirq a 
c:x:arparable injectioo protocol. A total of 100 units of IL-1 was 
administered to each DDJSe reoeivirq this therapy. Mice were period-
ically checked for survival. All mice survivirq this initial tUloor 
challen:ie am showirq oo visible signs of tum::>r growth after thirty-
five to fifty days were rechallen:JEd with the EL-4 tUloor. '!he re-
challen:ie ioocul.um was injected i.d. on the right flank between the 
site of the initial tUloor c:hallen:ie am drainin;J axillary lyirq;t>. 
nodes. 'Ihe Eir4 tUloor dose was equal to that given for the initial 
challen:ie am 00 further therapy was administered to these animals. 
Mice were evaluated periodically for survival. In separate experi-
ments, mice were rarxianly selected at successive time periods fol-
lowirq either initial or secorx3azy Eir4 challen;ie for .in vitro eval-
uation of lYll'Ploid immunological. responsiveness. 
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H. Radiolabelim 'l\mpr Target Ce1ls 
Either in yitl;:Q passaged EL-4, :RBI.r-5, YAC-1, IG62, or in vivo 
passaged EL-4 ascites tullDr tal:get cells were washed once after har-
vestin], resusperDed in HasS ani counted. A suspension of between 
3 x 106 am 1 x 107 tullDr cells was pelleted by centrifu:lation at 
400 x g for seven to ten minutes. '!he supematant was discarded ard 
the cell pellet resuspenjed in the residual HESS (150 ul). 'l\noor 
target cells were radiolabeled by incubation with 100 uci to 200 UCi 
Na251cro4 (51cr) (New Erqlard Nuclear, Boston, MA, or Amersham Co:cp-
oration, Arlirqtan Heights, IL) for forty to sixty minutes with 
freqUent agitation. 'lhe SJ.er labeled cells were pelleted, washed 
four times in HasS, ani resuspemed in oatplete medium for immediate 
addition to effector cells at 1 x 104 taI'get cells per well. 
I. T Cell Mediated <rYtotoxicity 
T cell-mediated, tullDr cell cytotoxic activity of ly.q:hoid 
tissues taken fran tullDr chall~ animals at varioos time points 
foll~ antitullDr therapy, was assessed follO!rlin;J pr<XJedures des-
cribed by Brunner ani colleagues (34). Mice were sacrificed by 
cervical dislocation. 'lhe spleen ani lynph nod.es drainirq the site 
of the tullDr dlal.19n39 were aseptically reiooved fran each animal, 
passed through a 6()-gau:Je wire mesh to obtain a cell suspension, arxi 
washed once in :aass. Eryt:h:rocytes in the splenic suspension were 
destroyed by rapid hypatanic lysis with distilled water, followed by 
several HESS washes. Splenic am lynph node effector cells were then 
resuspenjed in oatplete RPMI-1640 medium with ten percent FBS. 
Cytotoxic activity of all cell pc:p.1lations were dete.nni.ned at four 
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effector-to-target (E/T) ratios by serial diluticn of effector cell 
ooncentratia'lS, rarqinJ fJ:an 1 x io6 to 1.2 x 105 cells per well, in 
rourrl bottan chambers of 96-well tissue culture plates (Fal.c:ai Plas-
tics) • ~ rme effector cells were evaluated at the highest pos-
sible cell concentraticn allowin,;J for foor serially diluted E/T 
ratios. 'lhis variability was due to the low number of cells occas-
ionally obtained fJ:an these tissues. All E/T ratios ard oontrols 
were performed in triplicate (1 x io4 5J.cr labeled tumr target cells 
were added to each well in 100 ul of medium) • Total well volume was 
brought to 200 ul with media when necessa:ey. '!he cytotoxicity 
cultures were qently pelleted by centrifugation at 100 x q for five 
minutes. Followin;J a fCAJr-halr incubation period, the cultures were 
pelleted by centrifugaticn at 400 x q for five minutes. R.adiolabeled 
tumr target cells incubated witha.tt effector cells were used to 
detennine the spont.aneoJs cellular 5J.cr release. Maxilmlm cellular 
release was obtained by lysinJ labeled tumr targets with Nonidet P-
40 (NP-40) (Sigma Chemical co., st. Louis, K>). Released radiolabel 
was harvested by renovirq 130 ul of supematant fran each 'Well, am 
counted on a Beckman Gamma 4000 gamma radiation oounter (Beckman 
Instruments, Ioo. , Irvine, CA) with data expressed as CX>1.ll'lts per 
minute (CEM) • Results were expressed for each E/T ratio as percent 
specific release (PSR): 
PSR = 100 x CCEM in experimental well) - CaM in control well> 
(aM in NP-40 well) - (aM in control well) 
PSR data were represented grapiically as a furttion of culture dilu-
tion. Linear least square curve fittin;J usirq cmve Fitter-~ soft-
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ware (Interactive M:i.crCMare, :rrx:. , Imlblny, er) determined the best 
straight line though the PSR data points. Usin;J this analysis the 
slope of the line will vary deperxtinJ on the prqx>rtion of cytolytic 
cells and the efficiency of cytolysis in the effector pc:ptlation 
(290) • Results, extrapolated fran the fitted curve, are expressed as 
lytic units (L.U.) per cell culture ' with one L.U. defined as the 
inverse of the fraction of a 1 x 106 effector cell culture require:l 
to achieve ten percent specific release (43). 
J. Natura! Killer cell Activity 
'!he NK assay was performed in the same manner as that des-
cribed above for the cytotoxic T cell assay, except that the (51cr) 
radiolabeled target cell was the NK susceptible YAC-1 tum::>r cell 
line. Since NK activity is seen in uninm.mized animals, the deter-
mination of aey n¥:Xiulatiai of this parameter 1l'llSt be measured care-
fully against the control protocol mice. As di SOJSsed in the pre-
vious section, data are graprl.cally expressed as PSR, then cx:nverted 
to L.U. of activity. statistical evaluation of the data was deter-
mined by t-test analysis of the PSR for the 100 to 1 E/T ratio data 
points. 
K. Macrophage 'l\nooricidal Activation and Assessment 
1. 'Ihe 'lhioglyoolate Irxiuoer 
Brewer's thioglycolate broth (Difeo, Detroit, MI), used_ for, 
i. p. , injection of mice, was prepared as described by canpbell, §t 
al. (35). An autoclaved 100 ml aliquot of thioglycolate medium was 
oxidized by exposed to roan air for two JOOnths. '!he oxidized media 
was distributed in 5 ml aliquots and frozen at -200c for later use. 
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2. '1he Macrg:ilage Activators 
I.PS fran salnpnella tydlosa 0901 (Difoo, Detroit, MI), obtain-
ed in lyqilolyzed form, was rehydrated in HBSS, distr.ibrt:ed into 1 ml 
aliquots at a c:xn::entration of 100 u;Vml, arxi stored at -200c until 
needed. Cal A (Difoo, Detroit, MI), obtained in ctyStalline form, 
was also rehydrated in HBSS arxi stored at -200c. Preparation of~ 
parvym for use in this assay was the same as that described in sec-
tion B. of this chapter. 
3. 'Ihe Macrqilage Motoxicity AssaY 
'Ihe methods employed for this assay (37) are JOOdificatians of 
the technique originally described by Doe arxi Henson (70) • Mice were 
injected with 1 ml of aged thioglycolate broth, i. p. , arxi sacrificed 
by cervical dislocation four to five days later. Peritoneal exudate 
cells (PEC) were abt:ained by peritaieal lavage with 10 ml of HBSS 
conta~ ten units of hepari.Jv'ml (Difoo, Detroit, MI). '1he PECs 
were washed once in HBSS arxi resusperxied at 1. 3 x 106 cells/ml in 
carplete RFMI-1640 medium suwlemented with ten percent FBS. one 
hurrlred microliters of the suspensions were plated in 96-well micro-
titer plates. Nooadherent cells were eliminated after two hours of 
incubation by rerooving the culture medium arxi replacing it with 100 
ul of fresh RFMI-1640. After an additional twenty to twenty-four 
hours of incubation, the culture media was again rerooved arxi replaced 
with 80 ul of carplete mMI-1640 medium. 'lhe awropriate activators 
were then added in 100 ul volumes to each well in quadruplicate. 
'!Wenty to twenty-four hours later, 1 x 104 51cr-labeled target cells 
were added to each well in a 100 ul volume. After eighteen to twenty 
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hoUrS, the cultures were centrifug'Ed at 400 x q for five :mirnrt:es. 
seventy microliters of culture supernatant were carefully renDVed 
frcm each well arxi radioactivity determined usirq the Gamma 4000 
gaimna radiation counter. control cultures contained radiolabeled 
tunor tazqets incubated with nonactivated thioqlycolate-imuced, 
adherent PECs. Maxill'B.nn possible cellular release of 51.cr was cbtain-
ed by addinJ NP-40 to control cultures, or by disturl:>irq the pelleted 
target cells with rigorous pipettin;J before supernatant harvestirq. 
Data are expressed as PSR: PSR == 100 x 
(Mean CfM in activated well) - (Mean CfM in control well) 
(Mean CfM NP-40 well) - (Mean CfM in control well) 
L. Lymdloid Cell Proliferative Response 
Spleen arxi lYll'Pl oode cell suspensions, processed in the same 
manner as described for the cytotoxic T cell assay, were resusperded 
in oarplete m:MI-1640 medium suwlemented with two percent Fm. one 
humred microliter aliquots of spleen arxi lYll'Pl oode cells were 
plated in 96-well microtiter plates at 2 x ic5 arxi 1 x io5 cells per 
well, respectively. 
Mitanycin-c inactivated tunor cells were prepared by incu-
batirq 1 x io7 tunor cells with 25 u;;i of mitanycin-c in one ml of 
c::arplete m:MI-1640 medium for one hour. '1he cells were washed three 
times in Ha9S, arxi resusperded in oarplete m:MI-1640 medium with two 
percent FBS. F.ach stin:W.ator cell pop.llation was plated in tripli-
cate at 1 x 105 cells per well in 100 ul aliquots with spleen am 
ly:rrph node effector cell pop.llations. Spleen arxi lyq;il node effector 
cells were incubated alone to detennine a basal level of prolifer-
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ative activity. Duplicate cultures were pl].sed six hours with l UCi 
3H-thymidine after two arr:i five days of m:::ubatim. Cell cultures 
were harvested with the cambridge HID autanated cell harvester arxi 
radiolabel i.nc:mporatia'l for eadl sanpl.e was determined usin;J liquid 
scintillatiai specb:qilatanatry. Data are expressed as stilllll.atia'l 
irrlexes (SI): 
SI = Mean cm (Effector Cells+ stinul.ator Cells) 
Mean CfM (Effector Cells) 
M. In Vitro Effect of IIrl on EL-4 Pro1iferation 
lD vitro passaged EL-4. lynq;ilana cells were harvested fran cell 
culture, washed once in HBSS, resuspenied in catplete REMI-1640 
medium with ten percent FBS, am incubated at 5 x io4 cellsftNell in 
96 well microtiter plates. Various doses of IIrl, rargin;J fran 0.1 
to 25 units of IIrl activity, were added to the t\lllX)r cell micro-
cultures. All IIrl doses were tested in triplicate. Proliferative 
activity was assessed with a six hour 3H-thymidine pulse after one 
am two days of t\lllX)r cell incubation with IIrl. '!he cultures were 
harvested am OOl.lllted as described previously for other 3H-thymidine 
proliferative assays. 
N. Determination of Serom Antibody Titers Against the EL-4 
IJymphana 
1. Preparation am Fixation of the EL-4 Lysate 
EL-4 ascites suspensions were washed three times with saline, 
then resuspeOOed in 2. 5 ml of o. 5 percent NP-40 lysis hlffer per 
1 x 107 cells. '!he cells were incubated for ten minutes at 40c with 
oocasiooal vortexirXJ followai by oentriflgation at 700 x g for thirty 
minutes. '!he supematant was careful.ly decanted with 50 ul of this 
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cell lysate added to each well of a flexible 96-well microtiter plate 
(Falcon Plastics, No. 3911). '!he lysate was incubated in the wells 
at 37"c ovemight, allowin.1 the lysate to dry in each well. '!he cell 
lysate was fixed to the wells by the addition of 100 u1 of a 0.02 
percent glutaraldehyde (Sigma Chemical co. I st. I.oois, M'.>) in pxis-
P'late b.lffered saline (PBS) at roan tenprature for ten minutes. 'lhe 
wells were then washed three times with PBS before they were filled 
with a 0.1 percent gelatin (Sigma Olemical co., st. I.oois, M'.>) solu-
tion in PBS. After sixty minutes of incubation at roan 't:enq:>erature 
the plates were again washed three times with PBS, inverted, drained, 
arxi stored dry at 4"c covered with plastic wrap. 
2. Antibody Bin:lirg Assay 
mood sa:nples were c:btained fran mice receivin;J variQJS treat-
ment protocol animals by cardiac pmcture. '!he blood was allowed to 
clot at roan teq:>e:rature for several hours. Serum was separated by 
centrifugation at 700 x g for twenty minutes, decanted, am stored at 
-2ooC until needed. 
Fifty microliters of each serum sa:nple were added to the EL-4 
cell lysate coated microtiter plate wells in a mist chamber arxi 
incubated eighteen hours at 4"c. '!he 'Wells were washed six times 
with 0.1 percent gelatin in PBS am drained. one humred microliters 
of a 1:2000 dilution of horse radish peroxidase labeled affinity 
purified goat antibody to 100USe IgA+IgG+IgM heavy am light chains 
(Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) was added to 
each EL-4 lysate coated well. '!he antibody was incubated one hour at 
roan "terrperature. '!he wells were then washed ten times with the 0.1 
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percent qelatin in~ soluticn by inversicn, followed by four ll¥Jl:'e 
washeS with 0.1 percent qelatin in~ by aspiraticn with a pasteur 
pipet. After thorcugh drainirq 150 u1 of substrate oonsistirq of, 
o .1 mM 2. 2 '-Azioo-di (3-ethyl-benzthiazoline sulfonic acid) as sub-
strate am o. lM glycine citrate buffer pH 4. o at 2sOc am o. 02 per-
cent H2~, was added to each well. Followirq one hour of incubation 
color development of the substrates was measured by optical density 
at 405 nm with a MR-600 Microplate Reader (Dynatech Laboratories 
Inc. , Alexarrlria, VA) • '!he antibody titer will be detenn.ined usirq 
the ABC50 method described by Mi.men am Farr (203). 
A. Anti-tum:>r activity of c. parwm 
1. In vivo Sup:>ression of the Eir-4 ~by c. parvum 
Va:cyirg numbers of raiviable c. parvum oells wze admixed with 
in vivo passaged Eir-4 lyqilana cells, then injected, i.d., in the 
flanks of mice. In this manner, the bacterial dose required to sup-
press tumr growth was assessed. Pooled results of two experiments 
which yielded similar results, shown in Table 3, Wicate that sup-
pression of tumr growth was deperrlent upon the rrumber of bacteria 
injected with the tumr challenge. umer these experimental con:li-
tions, optimal protection against the tumr resulted when 2 x 109 
c. parvum cells wze admixed with the tum:>r challerqe. 'lhis dose of 
c. parvum was utilized for all further in vivo tumr protection 
experiments. lower oonoentrations of c. parvum proved to be less 
effective with 1 x 109 cells p:rot:ectirg fifty-seven percent of the 
animals am 1~108 resultirg in only a twenty percent ~ival rate. 
Animals which received the tumr challenge without local c. parvum 
therapy denalstrated no survival. 
Animals which survived the initial tumr challenge remained 
free of subsequent tumr develcpnent. 'lhese animals were rechal-
lenged with 5 x 103 EU-4 tumr cells thirty to sixty days later. As 
shown in Table 3, none of these animals survived. 'lhese results 
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suggest that no lcn;J-lastirg inm.mity was generated as a consequence 
of c. parwm treatment of the EL-4 lynphana. 
2. In vitro Macrophage Activation by c. parwm 
'lbioglyoolate imuced macrophages activated by a forty-eight 
hoUrs incubation with heat-killed c. parwm dena1strated tullK>ricidal 
activity against 5J.cr radiolabeled EL-4 am RBL-5 tum:>r target cells 
in a dose-depenjent manner as shown in Figure l, a represenative 
exanple of six experiments dena1stratirq similar results. Previous 
work by Wigzell (306) has correlated 5J.cr release fran radiolabeled 
tUIOOr targets with loss of cell viability as detennined by trypan 
blue dye exclusion. As little as l x io8 ~ parvum cells/ml 'Were 
able to activate peritoneal macrophages to a tullK>ricidal stage, with 
increasirq levels of cytotoxic activity peakirg at an activator dose 
of l x io9 bacterial cells/ml. 
Followirq sixteen hours of incubation with the c. parwm 
activator, SJ.er radiolabeled EL-4 tullK>r target cells dem:>nstrated no 
loss of viability as detennined by trypan blue dye exclusion (see 
Table 4). Tun¥:>r cell viability remained high after incubation with 
c. parvum activator ooncentrations rarqirq f:ran l x ioS to l x iolO 
bacteria/ml.. Likewise, I.PS dEm:>nstrated no toxicity to the tUIOOr 
cell targets in the ooncentration rarge utilized in the cytotoxicity 
assay, altho.:gh I.PS was cytotoxic to these cells at a c:oncentration 
of 100 ug/ml. 'lherefore, release of radiolabel in these experiments 
was not due to direct cellular toxicity by the activators in this 
system. 'Ihese data dem:>nstrate that c. parvum activates macrqilages 
to becane tuJIDricidal for experimental lynpianas, thereby suggestin;J 
TABLE 3. Suppression of the EL-4 Lymphoma by Corynebacterium parvum.a 
survival 
Primary Challenge Secondary Challenge 
Bacterial #Survivors/ #Survivors/ 
Number #Challenged (%) x2 #Challenged (%) 
-
2 x 109 13/13 (100) p < 0.01 0/13 (0) 
l x 109 8/14 (57) p < 0.01 0/8 (0) 
l x 108 2/10 (20) N.s.b 0/2 (0) 
EL-4 Alone 0/14 (0) 
aBacteria (0.1 ml) were admixed with EL-4 cells (0.1 ml) and injected i.d. into the 
right flank of each animal. 
bN.S., not significant; p> o.os, experiemnts were compared with those for animals 
injected with EL-4 alone. 
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Figure 1. Effect of in vitro c. paryum activation of thiogly-
oolate indl1oed ~ on the in:iuction of tullDricidal 
activity. Folladrq a 24 hour~ st.ilmJlation with 
~ Paryum, 51.cr radiolabeled Eir4 (•) an:l RBir-5 (A) 
'b.m¥:>r targets were added to the culture. After 16-18 
hairs of incubation the PSR of 51.cr was determined for 
each culture. Fac::h value represents the mean PSR of 
triplicate cultures ± STD. 
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TABIE 4. Eir-4 ~ Cell Viability Followirg Il"Dlbatiai 
With C. parvum am LPS Activators. 
AMXlNI'/ml ~(%) 
c. parvum 1 x iolO 89.6 ± 5.4 
c. parvum 1 x lo9 90.6 ± 3.1 
c. parvum 1 x loB 86.4 ± 5.1 
LPS 100 ug 46.2 ± 10.2 
LPS 10 ug 87.4 ± 4.0 
Medium 0 92.0 ± 2.4 
a2 x lo5 Eir-4 turoor target were in::ubated with activators 
in 96-well microtiter plates for sixteen boors. 
~iability was determined by trypan blue dye exclusicn. 
'!he data are expressed as the mean viability of 
duplicate cultures± the st:amard deviaticn. 
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that the .in vivo tuoor protective capability of .c..z. parvum ciJsezved in 
this experimental system may :be a result of local activation of 
macrqil.ages. 
B. In vivo Protective Effect of IL-1 Against the E!c4 IMtJ:hgna 
1. Effects of P388Dl Mac;rg;fulge Derived IL-1 
A series of .in vivo experiments were performed with IL-1 to 
irduce protective .llmnunity in the EL-4 lynpiana/~ pa:ryum treatment 
system. .Anilllals given the EL-4/~ parwm admixture were divided into 
tTNO groups. one 9mlp received no further therapy while the other 
group received, i.d., P388Dl macrqnaqe derived IL-1 therapy as des-
cr.ibei in Sectiai G of the Methods ani Materials chapter. Table 5 
summarizes the results ftan six experiments. ~tely eighty 
:percent of the animals in both protocol groups survived the initial 
c.hallen:Je. 'lhirty-five to fifty days later, animals which survived 
the primaey tuiror challen:Je, were rechallen;Jed with a similar EL-4 
tuoor dose with no further therapy. .Anilllals which received i. p. 
injections of IL-1 at the time of the primary tunw:>r c:hallen:Je, showed 
a statistically significant enhanced survival rate of 53.5 percent 
upon rechallerqe (p<0.02) when oc:mpared by d:rl.-square analysis to 
animals not given IL-1. SUrvivirq animals, given the EL-4/~ parvum 
admixture without IL-1, exhibited a rechallerqe survival rate of 20. 7 
percent. No statistical differences were denalstrated between re-
c.hallen;Jed animals initially treated with the EL-4/C. pa:ryum admix-
ture without IL-1, EL-4 with IL-1 alone, or EL-4 withcAit therapy. 
'Ihe survival c:m:ves for these animals followirg the primary 
tuoor c.hallen:Je are presented in Figure 2. .Anilllals receivirg EL-4 
TABLE 5. Suppression of the EL-4 Lymphoma by Corynebacterium parvwn and P388DlY 
Macrophage Derived IL-1.a 
Treatment 
Protocol 
EL-4 with 
~ parvum 
+ MD IL-1 
EL-4 with 
~ parvum 
EL-4 Plus 
MD IL-1 
EL-4 Alone 
Primary Challenge 
#Survivors/ 
#Challenged (%) 
43/53 (81.1) 
29/37 (78.4) 
7/30 
8/44 
(23.3) 
(18.2) 
Survival 
secondary Challenge 
#Survivors/ 
#Challanged 
23/43 
6/29 
1/7 
1/7 
(%) 
(53.5) 
(20.7) 
(14.3) 
(14.3) 
x2 
p < 0.02 
N.s.b 
aBacteria- (2-x-109 per 0.1 ml) were admixed with EL-4 cells (O.l ml) and injected i.d. 
into the flank of each animal. IL-1 was administered i.p. (O.l ml) from day o to 
day 9 post-tumor inoculation. A total of 100 units of IL-1 was administered per 
animal. 
~.s., not significant; p > 0.9, experimental was compared with animals receiving EL-4 
alone, IL-1 alone and surviving second challenge. 
U1 
~ 
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am c. paryum or EL-4 am c. parvum plus IL-1 showed nearly identical 
sw:vival pattems. Animals administered EL-4 alone or EL-4 plus IL-1 
therapy exhibited low sw:vival rates of 18.2 am 23.3 percent :respec-
tively, with no statistical difference shown between these sw:vival 
rates as determined by chi-square analysis. 
SUrvival curves for animals (which had sw:vived the initial 
challerge) followin;J a seoaDlly challen;Je with the tunDr are de-
picted in Figure 3. Animals which had initially received the EL-4 
challerge, alooe or with acxx:apany.in;J IL-1 therapy, showed a rapid 
drop in sw:vival to 14.3 percent by thirty days post rec:hallen;Je. 
Animals which initially received EL-4 am c. pazyum, or EL-4 am ~ 
pazyum plus IL-1, showed an enhanced sw:vival rate until approxim-
ately day forty-two, at which time the animals that had received EL-4 
am ~ pazyum exhibited a drq> in sw:vival to a level (20. 7 percent) 
not statistically higher I by t test analysis I than animals which had 
initially received either EL-4 alooe or EL-4 am IL-1. 
'Ibis data SU}1ests that systemically administrated P388Dl 
mamqmge derived IL-1 augmented inm.mity to the EL-4 lynphana such 
that a secorxi tunDr challerge did not progressively CJrcM to kill the 
animals. In contrast, redlallerged mice which received c. parvum 
trea"bnent without IL-1 dena1strated no statistically enhanced sur-
vival. Systemically administered IL-1 had no tunDr suppressive 
effect without the addition of a local administration of c. paryum. 
2. Effects of Murine ~inant IL-1 
An In vivo tunDr protection experiment was perfonned us.in;J 
recombinant :murine IL-1 obtained fran Hoffmarm-I.aRoche, Inc. In this 
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Figure 2. Effect of P388DlY macrqilage derived Ilrl therapy ai 
survival follC11lin;J the prilllaey Eir4 tultDr c:hallerge. 
Eir4 c:hallerged mice were treated with either c. 
paryum (X) I P38801Y macrqi1aq8 derived Ilrl (0) I 
c. paryum ard P388DlY macrqilage derived Ilrl Cb), or 
no treatment (•). Treatment am tuDDr injectia'l 
protocols were administered as described in sectiai G 
of the Methods am Materials chapter. 
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Figure 3. Effect of P38801Y macrqbaqe derived IIrl therapy on 
survival follOfotlin;J the seoorXlary Eir4 tunDr challen;re. 
Mice treated at the time of the primary Eir4 challerge 
with either c. parvum (X), P388DlY mac:rqilage derived 
IIrl (¢) , c. parwm ani P388DlY mac:rqilage derived 
IIrl (A), or no treatment (•), were given a seoord 
Eir4 challerge. Treatment ani tmoor injection proto-
cols were as administered as described in section G of 
the Methods arrl Materials chapter. 
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experiment animals received the primary Eir4 tunor challen;Je with 
local c. parvum therapy, i.d., plus i.p. therapy, with either 100 
units of Jllll"ine reoanbinant IIrl or unstinulated P388DlA oorxlitioned 
culture supematants. AnilDals which survived the initial bmm' 
challen;Je 'Were given a seocni Eir4 challen;Je thirty-five days after 
the primary tunr:>r dose was administered. Results fran this trial are 
shown in Table 6. Eir4 chal.len;Jed animals that received either ~ 
paxyum plus murine recanbinant IIr-1, or c. pu:yum plus unstimulated 
P388DlA oorditioned culture supematants deloonstrated similar sur-
vival rates of 93 ard 100 peroent, respectively, folla.rin:] the 
primary tunr:>r challen;Je. Animals that received the EL-4 challen;Je 
withrut therapy all died within thirty-two days (Figure 4). Follow-
irg the Eir4 recballerge, animals which received systemic recanbinant 
IL-1 therapy deloonstrated a 26 .1 percent survival rate, while animals 
which received the non-IIr-1 con:t:ainin:; supernatant, all succumbed to 
the tunr:>r (Table 6) • All recballen;Jed animals, that received c. 
paryum therapy plus the unstim.llated P388DlA culture supernatants 
rapidly died (within twenty-seven days) ard showed nearly identical 
sw:vival patterns with no prolon;iation of mean survival tine when 
coopared to animals that received the Eir4 as an initial challen;Je as 
detennined by t test analysis (Figure 5) • In oontrast, animals that 
had received II.r-1 up:>n initial challen;Je showed a nm:e gradual. de-
cline in recballerge survival, thereby qeneratirg a markedly pro-
lon;ed survival curve with the last death :recorded at day thirty-
seven as shown in Figure 5. '!he mean recballen;Je survival duration 
of 31.3 days for the IIrl treated animals was detennined to be 
TABLE 6. Suppression of the EL-4 Lymphoma by Corynebacterium parvum and Murine 
Recombinant IL-1.a 
Primary Challenge Secondary Challenge 
Treatment #Survivors/ #Survivors/ 
Protocol #Challenged (%) #Challenged (%) 
--
EL-4 with 
~ parvum 40/43 (93. 0) 6/23 (26.1) 
+ IL-1 
EL-4 with 
~ parvum 
+ Non-IL-lb 
14/14 (100) 0/4 (0) 
EL-4 Alone 0/10 (0) 0/5 (0) 
aBacteria (2 x 109 per 0.1 ml) were admixed with 5 x 103 EL-4 cells (O.l ml) and 
injected i.d. into the flank of each animal. IL-1 was administered i.p. 
(O.l ml) on alternate days from day o to day 9 post primary tumor inoculation. 
bNon-IL-1, P388DlA unstimulated conditioned culture supernantant. 
°' ...... 
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Figure 4. Effect of llll.lrine reccmbinant IL-1 therapy on SUl:Vival 
follCJWin;1 the primaJ:y EI.r-4 tulror c.hallen;Je. EI.r-4 
challen:Jed mice were treated with either c. paryum am 
llll.lrine reccmbinant IL-1 (6), C. paryum am P388DlA 
unstimulated c:xnlitioned media (~), or no treatment 
(•). Treatment am tulror injection protocols were 
administered as described in section G of the Methods 
am Materials chapter. 
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Figure 5. Effect of llllrl.ne :rec:anbinant IIrl therapy on survival 
followin] the secxn3aJ:y Eir-4 tum:>r challerge. Eir-4 
dlallcm;ied mice were treated with either c. pazwm am 
111.1rine recanbinant nr i (A) , c. pazwm am PJssolA 
unstinll.ated c:xnlitialed media <<» , or no treat:Jrent 
(•) , wre qiven a seocni Eir-4 challen;e. Treat:Jrent 
am 'b.mm' injectioo protocols wre as administered as 
described in sectioo G of the Methods am Materials 
dlapter. 
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significantly enhanoed (p < 0.02) when carpared to the 25.2 day mean 
survival duration of mice which received the unstinW.ated P388Dl 
con:litioned supematant. 
'Ihese data deloonstrate that a combination of local adjuvant 
therapy (C. paryum), in conjunction with systemic recanbinant IIr-1 
administration, resulted in a statistically enhanoed survival dur-
ation for rechallen;red animals. '1hese results are similar to those 
obtained with macrqilaqe derived IIr-1. 
c. In vitro Effect of IL-1 cm the Eir4 lynpigna 
Various anamts of IIr-1 were added to actively prolife:ratin;J 
in vitro Eit-4 cultures as described in section M of the Methods arxi 
Materials chapter. As shown in Figure 6, fran o. 75 to 12.5 units of 
exogenously added IIr-1 had no deleterious or enhanciIX] effects on the 
in vitro proliferative capacity of Eir4 cultures after twenty-four or 
forty-eight hoors of irx::ubatiai. 
D. Assessn-ent of Eir4 Reactive Antibody Titers Against the EI.c4 
IMN2bana 
In Table 7, serum obtained frcm animals which :received the 
Eir4 tuioor challen;re either alone, with c. parvum. or with c. paryum 
plus macrophage derived IIr-1, were tested for Eir4 reactive antibody 
titers against the Eir4 lyqbana. It was apparent that no increase 
in antibody titers was detected in the sera of mice challen;re4 via 
aey of the experimental protocols when tested periodically up to 
eighteen days after the initial 'l:ulror challen;re. Mice cured of the 
tunor via c. paryum plus IIr-1 therapy also deloonstrated no detect-
able levels of Eit-4 reactive antibody up to 40 days after the tUlOOr 
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Figure 6. Effect of murine recarribinant IL-1 on the in vitro 
proliferation of EL-4 turror cells. EL-4 cells were 
cultured with or without M.lrine recombinant IL-1 for 
24 ~) ani 48 hours (•) • EL-4 cell proliferation was 
determined by cellular 3H-thymidine inco:i:poration as 
described in section M of the Methods ani Materials. 
Each value represents the mean PSR of triplicate 
cultures ± STD. 
0 N 
0 
N
 ~ 0 0. 0 
0 0\ 
0 co 
-~~ 
0 
0 ....
.
 
(c-)o L 
x
 
r4d:> 3N
IO
lr4A
H
.1.-H
C
 
0 co 
0 It) 
N
 -0 -co 
co 
~
 
N
 0 
68 ...J 
~
 
' -I ...J 
.
.
.
.
 
z 
<t 
z 
ffi :: 
0 u 
w
 
ct: 
w
 
z 
ct: 
:J 
~
 
"
'-
0 II> 
.
.
.
.
 
z 
:J 
TABLE 7. Serum Antibody Levels Reactive With the EL-4 
Lymphoma Following the Primary EL-4 Tumor 
Challenge.a 
Serum Antibody Titer 
DAY POST PRIMARY TUMOR CHALLENGE 
TREATMENT 
PROTOCOL DAY 6 DAY 9 DAY 13 DAY 18 DAY 40 
EL-4 Alone <10 <10 <10 <10 Noe 
EL-4 with 
~ parvum <10 <10 <10 <10 ND 
EL-4 with 
~ parvum 
Plus MD IL-1 <10 <10 <10 <10 <1ob 
No Treatmentc ND ND ND ND <10,25 
Hyperimmuned 
69 
Against EL-4 ND ND ND ND 370,115,25 
<10,<10 
aserum antibody titer determined by ELIZA as described in 
section N of the Methods and Materials chapter. 
bAnimals with no visible sign of tumor developmen, forty 
days after the EL-4 challenge, were considered cured 
of the tumor. Three animals were tested, all with 
antibody titers <10. 
cNormal C57Bl/6 serum. 
dAnimals were repeatedly immunized with mitomycin-c 
treated EL-4 tumor cells. 
eND, Not determined. 
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challenge. A majority of mice hyperimmunized by repeated injection 
with mitamycin-c treated EL-4 tum::>r cells did show an elevated anti-
body titer to the tum::>r. 'Ihese data i.rrlicate that systemically 
administered IIr 1 was unable to augment the humoral inunune response 
against the Eir-4 lyng;>homa, within the detectable limits of the ELISA 
system employed. 
E. Effect of systemically Administered IIr-1 Upon the Number of 
Cells Recovered from the Lymph Nodes Draining the Site of the 
Eir-4 'I'Ulror Challenge 
Animals which received Eir-4 and c. parvum or Eir-4 and c. 
pazyu:m. plus IIr-1 were sacrificed at various time periods following 
both the EL-4 primacy and secorrlal:y challenge. 'Ihe total number of 
lyrrph node cells sequentially recovered from the regional axillai:y 
and brachial lyrrph nodes drainiDJ the tum::>r injection site following 
the secorrlal:y Eir-4 challenge is presented in Figure 7. Mice that re-
ceived both tum::>r protection protocols demonstrated marked increases 
in recovered lyrrph node cell numbers soon after the Eir-4 rechallenge. 
Although, both groups demonstrated increased cell numbers, IIrl 
treated animals demonstrated a significantly greater response two and 
four days after the rechallenge, when carpared to animals not given 
IIr 1. 'Ihe lynph node cell numbers in both protocol groups decreased 
by day five after the rechallenge, with no differences in cell number 
noted between the two groups subsequently. 
Initially, organ weights were detennined for lynph nodes 
drainiDJ the site of the primacy tum::>r challenge for IIr-1 and non-
IIr-1 treated mice. However, at early time points lyrrph nodes were 
71 
Figure 7. Effect of P388DlY macrophage derived IL-1 therapy on 
the lymfilocyte cell mnnber in the lymfil nodes draining 
the site of the Eir-4 tumor challenge. Mice treatErl at 
the time of the primacy EL-4 challenge with either 
c. pa+yum (•) or c. pa+yum plus P388DlY macrophage 
derived IL-1 (A), were given a second Eir-4 challenge 
35 days after the initial Eir-4 challenge. 'Ihe lymfil 
nodes cell mnnber was detennined for lynph nodes 
draining the site of the tumor challenge at various 
time periods for each group f ollowirg the second Eir-4 
tumor challenge. Each value represents the mean lyitpi 
node cell number of there mice ± STD. 
72 
0 -m 
"' 
"
 
~
 
z 
"' 
.
.
.J 
.
.
.J 
c( 
:J: 
u
 
"
' 
0:: 
0:: 
0 :! 
::> 
.
.
.
 
v
 
... 
en 
0 0.. 
en 
~ 0 
0 
o
 
m
 
~
 
v
 
N
 
o
 
m
 
~
 
v
 
N
 
o
 
m
 
~
 
v
 
N
 
o
 
~
 
N
 
N
 
N
 
N
 
N
 
-
-
-
73 
too Slt1al.l to assess weights accurately. To overcome this difficulty, 
total lynph node cell numbers were obtained for each treatment 
protocol animal group in a secorrl series of experiments. Pooling of 
data obtained from both protocols was acc::oirq;>lished by calculating the 
percent change of lynph node weight or lYJIP:l node cell number between 
mice given c. pazyum arrl c. pazyum plus IL-1. Pooled results for 
days 4, 8, 13, arrl 17 yielded a percent change of + 10%, +6%, -19%, 
an:l -3% respectively. '!his data did not reflect arr:/ marked nodul-
ation of lynph node mass due to IL-1 therapy following the prima:cy 
tumor chall~e. Only data from animals without tumor were utilized 
in these calculations since animals with palpable tumor (generally 
detectable at day 12 to 15) developed corresporxlingly enlarged lynph 
nodes draining the tumor site regardless of previous treatment (data 
not shc::MI'l). 'Ihese results suggest that, while IL-1 therapy did not 
modulate gross lYJIP:l node mass following the prima:cy tumor chall~e, 
IL-1 did induce accelerated regional lynph node cell proliferation 
andjor the stimulation of lymphoid cell convergence to the regional 
lynph nodes draining the site of the tumor rechall~e following a 
second exposure to the EL-4 tumor. 
F. Effects of systemically Administered IL-1 Upon Splenic arrl 
Lymph Node in vitro Correlates of Immunity Directed Against the 
EL-4 Lymphoma 
In a series of experiments, animals were given an EL-4 tumor 
chall~e with c. pazyum therapy plus either: macrophage derived IL-
1, murine recombinant IL-1, control HSA, or no aocompanying i.p. 
therapy. 'Ihese mice were assessed for either splenic or lYJIP:l node 
cytotoxic T cell activity, NK activity, or lymphoproliferative 
responsiveness to the EI.r-4 lymphoma, followin:J both primacy arrl 
secomary t\lll'Or challenges. 
1. cytotoxic T Cell Activity 
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As shown in Table a, it is apparent that spleen arrl lymph node 
cells derived from animals uniergoin:J an initial EI.r-4 t\lll'Or challenge 
either with the EI.r-4 t\lll'Or alone, EI.r-4 arrl the protective c. paryum 
therapy, or EI.r-4 arrl c. paryum plus macrophage derived IIr 1, demon-
strated no detectable T cell cytolytic activity against 51cr radio-
labeled EI.r-4 t\lll'Or targets greater than one L.U. 'Ihe lack of lytic 
activity by spleen cells was demonstrated by periodic testin:] between 
day three arrl day seventeen followin:] the primacy t\lll'Or challenge. 
Lymph node cell populations, derived from these animals, were tested 
periodically for activity from day eight to day seventeen followin:] 
the primacy t\lll'Or challenge arrl showed a similar lack of cytolytic T 
cell activity against the EI.r-4 t\lll'Or targets. 
Similar results, shown in Table 9, were obtained when lymph 
ncx:ie arrl spleen cell populations derived from EI.r-4 rechallenged 
animals protected initially with c. paryum plus either murine recomb-
inant IIr-1, macrophage derived Ilr-1, or HSA control injection ther-
apy, were tested for cytolytic activity against EI.r-4 targets thirty-
five days after the primacy challenge (day o post rechallenge) ~ Fol-
lowin:J rechallenge with the EI.r-4 lymphoma, the lymph node arrl spleen 
cell populations from these groups of animals showed no cytolytic 
response greater than one L.U. to the EI.r-4 lymphoma. 
TABLE a. Effect of macrophage derived IL-1 on Splenic and Lymph Node T Cell cyto-
toxicity Against the EL-4 Lymphoma Following Primary EL-4 Tumor Challenge. 
DAYS POST 
PRIMARY 
CHALLENGE 
3 
6 
8 
10 
13 
17 
EL-4 
<ld 
<l 
<l 
<l 
<l 
<l 
SPLEEN CELL POPULATIONSa,b 
EL-4 with 
~ parvum 
<l 
<l 
<l 
<l 
<l 
<l 
EL-4 with 
~ parvum 
Plus IL-1 
<l 
<l 
<l 
<l 
<l 
<l 
LYMPH NODE CELL POPULATIONSa,c 
EL-4 
ND 
ND 
<l 
<l 
<l 
<l 
EL-4 with 
~ parvum 
ND 
ND 
<l 
<l 
<l 
<l 
EL-4 with 
~ parvum 
Plus IL-1 
ND 
ND 
<l 
<l 
<l 
<l 
aspleen and lymph node effector cell suspensions represent cells pooled from three 
animals sacrificed from each treatment protocol group. 
bRadiolabeled EL-4 YAC-1 tumor targets (1 x 104) were incubated with effector spleen 
cell populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as 
described in the Methods chapter. 
cRadiolabeled EL-4 YAC-1 tumor targets (1 x 104) were incubated with effector lymph 
node cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four 
hours as described in the Methods chapter. 
dData are represented as L.U. of activity at ten % specific release per 1 x 106 
effector cells as described in section I of the Methods and Materials chapter. 
-..J 
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TABLE 9. Effect of Murine Recombinant (MR) and Macrophage Derived (MD) IL-1 on 
Splenic and Lymph Node T Cell Cytotoxicity Against the EL-4 Lymphoma 
Following the Secondary EL-4 Tumor Challenge. 
SPLEEN CELL POPULATIONSa,b LYMPH NODE CELL POPULATIONa,c 
DAYS POST EL-4 with EL-4 with EL-4 with EL-4 with EL-4 with EL-4 with 
SECONDARY ~ parvum ~ parvum ~ parvum ~ parvum ~ parvum ~ parvum 
CHALLENGE + HSA + MR IL-1 + MD IL-1 + HSA + MR IL-1 + MD IL-1 
0 <ld <1 <1 <1 <1 <1 
3 <1 <1 <1 <1 <1 <1 
6 <1 <1 <1 <1 <1 <1 
aspleen and lymph node effector cell suspensions represent cells pooled from three 
animals sacrificed from each treatment protocol group. 
bRadiolabeled EL-4 tumor targets (1 x 104) were incubated with effector spleen cell 
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as 
described in section I of the Methods and Materials chapter. 
CRadiolabeled EL-4 tumor targets (1 x 104) were incubated with effector lymph node 
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours 
as described in section I of the Methods and Materials chapter. 
dData are represented as L.U. of activity at 10% specific release per 1 x 106 
effector cells as described in section I of the Methods and Materials chapter. 
...J 
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'Ihese data suggest that IL-1 therapy was not able to elicit 
the development of a notable in vitro T cell cytolytic response in 
the spleen or regional lymph nodes in animals following the primary 
Eir4 tumor challenge nor in cured mice which were treated with IIr-1 
am then exposed to a secorxl tumor dose. 
2. Natural Killer Cell Activity 
Repeated periodic assessrrents were made of NK activity of 
spleen cell populations derived from animals urrlergoing an initial 
Eir4 tumor challenge either with the Eir4 tumor alone, Eir4 am c. 
paryum therapy, or Eir-4 arrl c. paryum plus macrophage derived IIr-1. 
Results of a typical experiment, presented in Table 10, showed a 
degree of fluctuation in the amount of lytic activity against YAC-1 
tumor targets in tests perfonned from day to day. However, compared 
differences in L.U. between spleen cell populations on individual 
days shows no pattern of augmented NK activity as a result of sys-
temic administration of macrophage derived IIr-1. Results of t test 
analysis corrparing the PSR of the 100 to 1 E/I' ratio data points for 
the three spleen cell populations tested on each day, established 
that no statistical differences in NK activity were seen between 
these groups on days three, eight, ten, arrl thirteen following the 
primary tumor challenge. On day six, animals which received no ther-
apy or c. paryum therapy with the Eir-4 challenge, demonstrated a sta-
tistically enhanced cytolytic response when compared to mice that had 
received Eir-4 arrl c. parvum plus IIr-1 therapy. '!his result was re-
versed on day 17, when the IIr-1 treated mice demonstrated an enhanced 
development of NK activity, when compared to animals not given IIr-1. 
TABLE 10. Effect of Macrophage Derived IL-1 on Splenic and Lymph Node Natural Killer 
Cell Activity Against YAC-1 Tumor Targets Following the Primary EL-4 Tumor 
Challenqe. 
DAYS POST 
PRIMARY 
CHALLENGE 
3 
6 
8 
10 
13 
17 
SPLEEN CELL POPULATIONSa,b 
EL-4 EL-4 with EL-4 with 
~ 12arvum ~ 12arvum 
+ IL-1 
3.22d 2.70 2.30 
2.08 1.91 l. 33 
3.13 2.74 1.47 
<l <l 1.14 
2.70 3.03 3.33 
<l <l 2.00 
LYMPH NODE CELL POPULATIONSa,c 
EL-4 EL-4 with EL-4 with 
~ 12arvum ~ 12arvum 
+ IL-1 
ND ND ND 
ND ND ND 
<l <l <l 
<l <l <l 
<l <l <l 
<l <l <l 
aspleen and lymph node effector cell suspensions represent cells pooled from three 
animals sacrificed from each treatment protocol group. 
bRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector spleen cell 
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as 
described in section J of the Methods and Materials chapter. 
CRadiolabeled YAC-1 tumor targets (l x 104) were incubated with effector lymph node 
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours as 
described in section J of the Methods and Materials chapter. E/T ratios of 
25:1 and 12.5:1 only were assayed for the EL-4 alone mice on day eight. 
doata are represented as L.U. of activity at ten percent specific release per 1 x 106 ~ 
effector cells as described in section I of the Methods and Materials chapter. 
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NK activity of lynph node cell populations were also deter-
mined. SUfficient cell numbers for assessment of NK activity were 
not obtained from the regional lynph nodes drainirg the site of the 
tumor challenge until the eight days after the primacy EL-4 chal-
lenge. As shown in Table 10., NK activity of lynph node cells ob-
tained from animals given the EL-4 challenge alone, or EL-4 with c. 
paryum or EL-4 with c. paryum plus macrophage derived II.r-1, demon-
strated no detectable NK activity above one L.U. from eight to seven-
teen days followirx] the primacy tumor challenge. 
Both lynph node and spleen cell populations obtained from 
animals survivirx] the initial EL-4 challenge with c. parvum plus 
either murine recanbinant II.r-1, macrophage derived II.r-1, or HSA ther-
apy, were tested for NK activity thirty-five days after the primacy 
challenge (day o post rechallenge), and then on days three and six 
followirx] the secon:Jacy EL-4 challenge. As shown in Table 11. , 
spleen cells obtained from II.r-1 treated animals demonstrated no lytic 
activity greater than one L.U. either innnediately before beirq given 
the secorrl EL-4 tumor challenge or on days three and six after the 
rechallenge. 
Cells obtained from regional lynph nodes drainirg the site of 
the tumor rechallenge of these mice were also assessed for NK 
activity. Results of these experiments, also presented in Table 11, 
show that the lynph node cell populations obtained from the II.r-1 
treated animals were equally unable to develop NK activity greater 
than one L.U. up to six day after the secorxi EL-4 challenge was 
administered. Control anilnal.s which received HSA injections along 
TABLE 11. Effect of Murine Recombinant (MR) and Macrophage Derived (MD) IL-1 on 
Splenic and Lymph Node Natural Killer Cell Activity Against YAC-1 Tumor 
Targets Following the Secondary EL-4 Tumor Challenge. 
SPLEEN CELL POPULATIONSa,b LYMPH NODE CELL POPULATIONsa,c 
DAYS POST EL-4 with EL-4 with EL-4 with EL-4 with EL-4 with EL-4 with 
SECONDARY ~ parvum ~ parvum c. :garvum ~ :garvum ~ :garvum ~ :garvum 
CHALLENGE + HSA + MR IL-1 + MD IL-1 + HSA + MR IL-1 + MD IL-1 
0 l.osd <l <l <l <l <l 
3 <l <l <l 1. 63 <l <l 
6 <l <l <l 1.90 <l <l 
aspleen and lymph node effector cell suspensions represent cells pooled from three 
animals sacrificed from each treatment protocol group. 
bRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector spleen cell 
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as 
described in section J of the Methods and Materials chapter. 
cRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector lymph node 
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours 
as described in section J of the Methods and Materials chapter. 
dData are represented as L.U. of activity at 10% specific release per 1 x 106 
effector cells as described in section I of the Methods and Materials chapter. 
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with the protective c. pai:yum therapy did deloc>nstrate NK activity 
greater than one L.U. on days three and six, although in neither case 
did this activity exceed two L.U. 'Ihese data irx:lica.te that NK activ-
ity did not appear to be enhanced in c. paryum treated animals which 
received IIrl, following either the primary or secon:lary tumor chal-
lenge. suggesting that enhancement of NK activity does not appear to 
account for the IIr 1 tumor protective effect. 
3. Lymphoproliferative Responsiveness 
In vitro splenic proliferative responsiveness to Eir4 and YAC-
1 stimulator tumor targets was assessed following a secon:lary Eir4 
tumor challenge. Splenic populations from mice that had sm:vived the 
primary Eir4 challenge with the aid of protective c. pacyum therapy 
plus either control HSA therapy, macrophage derived IIrl therapy or 
murine recombinant IIrl therapy were evaluated. Proliferative re-
sponsiveness was detennined sequentially for these groups of mice on 
the day animals received the secoooary Eir4 challenge and on days 
three and six following the rechallenge. 'Ihe results are presented 
for proliferative responsiveness to the Eir4 and RBI.rs lymphoma stim-
ulator cells in Figures 8 and 9, respectively. Both Figures have 
identical Y axis scales to allow easier ccmq;>arisons from one Figure 
to the other. Animals which received macrophage derived IIr 1 therapy 
demonstrated a lOOdest yet significantly enhanced response to the Eir4 
lymphoma (Figure 8) on day three (SI= 3.28) and day six (SI= 4.85). 
Such an enhancement was not seen in the II.rl treated animals which 
were assessed innnediately before the rechallenge (day o) • However, 
the spleen cells from the same II.rl treated animals did not resporrl 
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to YAC-1 tum:>r cells (Figure 9) on days three or six (SI = 0.94 an1 
1.33 respectively) when identically derived cell populations were 
respondin;J to the EL-4 stimulator cells. '!his response to the EL-4 
ly.rrphoma was shown to be significantly enhanced (p < o. 001) when 
corrpared to the responsive to YAC-1 stimulator cells on both days 
three an1 six, as detennined by t test analysis. 
Rechallenged mice which had received the HSA injections shOINed 
a statistically enhanced (p <.001) yet weak proliferative response to 
the EL-4 lymphoma (SI = 2.3) three days after the EL-4 rechallenge 
(Figure 8). However, no statistically augmented response (SI = 1.47) 
was elicited from HSA treated mice on day six follOINi.rq the rechal-
lenge. No response to YAC-1 stimulator cells (Figure 9) was noted 
for these animals on either day three or day six (SI = 0.81 an1 0.96 
respectively). Although this weak spleen cell proliferative response 
to the EL-4 lymphoma was observed three days after the tum:>r rechal-
lenge in HSA treated mice, the splenic proliferative response to the 
EL-4 lymphoma, generated by the macrophage derived IL-1 treated 
animals, was shown to be even statistically greater (p < 0.002) than 
the response produced by the HSA treated animals. 
Spleen cells from murine recombinant IL-1 treated animals were 
likewise assessed for proliferative responsiveness to EL-4 an1 YAC-1 
stimulator cells foll01Ni.rq a secorxia.ry tum:>r challenge. Results also 
presented in Figures 8 an1 9 respectively, were remarkably similar to 
those produced by animals which received macrophage derived IL-1. 
Recombinant IL-1 treated mice demonstrated a modest yet significantly 
enhanced response to the EL-4 lymphoma on day three (SI = 3.11) an1 
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Figure 8. Effect of P388DlY :nacrophage derived IL-1 therapy on 
in vitro splenic proliferative responsiveness to EL-4 
and YAC-1 tUIOC>r cells following the secorrlary EL-4 
tUIOC>r challenge. Mice treated with either c. parvum 
plus P388DlY :nacrophage derived II.rl or c. parvum plus 
HSA which survived a primaey EL-4 tUIOC>r challenge, 
were given a secorxi EL-4 challenge. Spleen cell 
populations derived from these two groups of mice were 
cultured 48 hours with mitamycin-c treated EL-4 or 
YAC-1 stimulator cells. Spleen cell proliferative 
responsiveness to the stimulator cells was determined 
by cellular 3H-thymidine incorporation as described in 
section L of the Methods and Materials chapter. Each 
value represents the mean SI of triplicate cultures 
± STD. 
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Figure 9. Effect of murine :recanbinant IL-1 therapy on .in vitro 
splenic proliferative responsiveness to EL-4 am YA0-1 
tum::>r cells followirq the sec:omary EL-4 tum::>r c:tlal.-
lerge. Mice treated with either c. parvum plus :mrine 
recanbinant IL-1 or c. parvum plus HSA Mlich survived 
a primary Eir4 tunDr dlal.lerge, were given a seocni 
EL-4 c:tlal.lerge. Spleen cell pop.tl.atioos derived frail 
these two 9J:Q1PS of mice were cultured 48 hours with 
mitanycin-c treated EL-4 or YA0-1 stinlll.ator cells. 
Spleen cell proliferative responsiveness to the stim-
ul.ator cells was determined by cellular JH-thymid.ine 
incorporation as described in section L of the Methods 
am Materials c:hapter. Fach value represents the mean 
SI of triplicate cultures ± STD. 
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day six (SI = 3.66) following the Eir4 rechallerqe. '!his response 
was not seen in the IL-1 treated mice which were assessed inunediately 
before the tunv:>r rechallerqe (day O post rechallen;e). Spleen cells 
from the same reoanbinant IL-1 treated animals did oot responi to 
YAC-1 tunv:>r targets en either days three or six (SI = 0.86 am 1.27, 
respectively) • 'lbese splenic responses to the Eir4 l}'lllilana were 
shown to be significantly enhanced (p<0.001) when cxmpared to the 
response to YAC-1 stimulator cells both en days three am six. 
once again, the proliferative response generated by IL-1 
treated animals to the Eir4 lyqilana was statistically greater, both 
on day three (p<0.05) am day six (p<0.001), when cxmpared to the 
weaker response produced by the HSA treated oontrol animals. 
Followin;J the initial Eir4 tunv:>r challen;e, as shown in Table 
12, no responsiveness was demnstrated by IL-1 treated animals to the 
Eir4 antigen in oontrast to the enhanced response seen after the 
secoMary Eir4 dlal.lerqe. '!his time oc:m"Se study, initiated three 
days am eOOing fourteen days after the primary challerqe, detected 
no proliferative response of spleen cells from IL-1 treated animals 
greater than 1. 63 (seen on day fourteen post rechallerqe) • Anllnal.s 
that received the Eir4 dlal.lerqe without treatlllent also failed to 
generate a proliferative stimulation Wex to the Eir4 lynpioma 
greater than 1. 58 as seen on day seven. Anllnal.s that received Eir4 
with c. paryum alone dena'lstrated a weak proliferative response to 
the Eir4 antigen (SI = 2.43) on day fourteen followinj the primary 
dlal.lerqe. '!his group of animals failed to generate aey marked 
proliferative response SI > 2.0) fran day three to day ten. 
TABLE 12. Effect of P388DlY Macrophage Derived IL-1 on the Spleen Cell Proliferative 
Response to the EL-4 Lymphoma Following the Primary EL-4 Tumor Challengea. 
STIMULATION INDEX 
DAYS POST PRIMARY CHALLENGE 
TREATMENT 
PROTOCOL DAY 3 DAY 7 DAY 10 DAY 14 
-
EL-4 Alone o.86 + o.34b 1.58 ± 0.10 0.70 ± 0.22 1.32 ± 0.21 
EL-4 with 
~ parvwn 0.79 ± 0.15 1.91 ± 0.16 0.97 ± 0.30 2.43 ± 0.11 
EL-4 with 
~ parvum 1.53 ± 0.23 1.17 ± 0.17 1.18 ± o. 39 1.63 ± 0.16 
+ IL-1 
aspleen effector cell suspensions represent cells pooled from three animals sacrificed 
from each treatment protocol group. Mitomycin-c treated EL-4 lymphoma cells 
(1 x 105) were incubated two days with various effector cell populations (2 X 105 
cells) in a 0.2ml volume. 3H-thymidine incorporation was determined as described 
in section L of the Methods and Materials chapter. 
bData are expressed as the mean stimulation index of triplicate cultures ± the 
standard deviation. 
()I) 
()I) 
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'Ihese data imicate that both macrophage derived arrl murine 
recombinant fonns of systemic Ilrl therapy were able to elicit a 
sequential enhan::lement of the splenic proliferative response in EI.r-4 
rechallerged animals. '!his response stron:Jly suggests specificity 
for the EI.r-4 tmoor; the tmoor antigen seen by these animals at the 
time of IIr-1 treatment. '!his response was shown to be markedly 
strorger arrl mre prolorged than responses generated by control HSA 
treated mice. 
unlike the enharx::ed proliferative response seen in the spleen 
cells fram rechallerged IIr-1 treated mice to mitanycin-c inactivated 
EI.r-4 stimulator cells, no detectable increase in responsiveness was 
generated in lynphoid cells taken frail regional lyitpl nodes drainin:J 
the tmoor chal.lerge site. Results obtained for lyitpl node cells, ob-
tained periodically from mice followirg both the primary arrl secom-
ary EI.r-4 tmoor chal.lerge, are shown in Tables 13 arrl 14 respectively. 
seven days after the primary EI.r-4 chal.lerge, a weak proliferative 
response (SI == 2.10) was generated in mice that received EI.r-4 with 
C. parvum plus macrophage derived Ilrl. '!his proliferative response 
was not seen when later assessed at day ten arrl day fourteen. Al-
though the !Ir 1 treated animals did dem:::>nstrate a weak proliferative 
response at day seven, animals that did not receive Ilrl also dem:::>n-
strated an equally weak proliferative response to the EI.r-4 stimulator 
cells. 'Ihus, !Ir 1 treatJnent did not appear to be responsible for 
this weak response generated early after the initial tmoor chal.lerge. 
'!he response seen in mice treated with c. parvum alone also .declined 
by day ten after the primary chal.lerge. 
TABLE 13. Effect of P388DlY IL-1 on Lymph Node Cell 
Proliferative Responsiveness to the EL-4 
Lymphoma Following the Primary EL-4 Tumor 
Challengea. 
STIMULATION INDEX 
DAYS POST PRIMARY CHALLENGE 
TREATMENT 
90 
PROTOCOL DAY 7 DAY 10 DAY 14 
EL-4 Alone Nob ND 1.65 ± 0.21 
EL-4 with 
~ parvum 2.30 ± 0.16C 1.00 + 0.30 1.23 ± 0.11 
EL-4 with 
~ parvum 2.10 ± 0.17 1.10 ± 0.39 1.15 ± 0.16 
+ IL-1 
aLymph Node effector cell suspensions represent cells 
pooled from three animals sacrificed from each 
treatment protocol group. Mitomycin-c treated EL-4 
lymphoma cells (1 x 105) were incubated two days with 
various effector cell populations (1 X 105 cells) in 
a 0.2ml volume. 3H-thymidine incorporation was 
determined as described in section L of the Methods 
and Materials chapter. 
bND, not determined. 
CData are expressed as the mean stimulation index of 
triplicate cultures ± the standard deviation. 
TABLE 14. Effect of P388DlY Macrophage Derived IL-1 on the Lymph Node Cell 
Proliferative Response to the EL-4 Lymphoma Following the Secondary EL-4 
Tumor Challengea. 
STIMULATION INDEX 
DAYS POST SECONDARY CHALLENGE 
TREATMENT 
PROTOCOL DAY 5 DAY 7 DAY 10 DAY 14 
EL-4 Alone Nob ND ND 1.67 ± 0.07 
EL-4 with 
~ parvum 1.04 ± o.1ac 2.16 ± 0.15 0.89 ± 0.30 1.20 ± 0.14 
EL-4 with 
~ parvum 1.73 + 0.11 1.92 ± 0.09 1.11 ± 0.20 1.20 ± 0.17 
+ IL-1 
aLymph Node effector cell suspensions represent cells pooled from three animals 
sacrificed from each treatment protocol group. Mitomycin-c treated EL-4 lymphoma 
· cells (l x 105) were incubated two days with various effector cell populations 
(l X 105 cells) in a 0.2ml volume. 3H-thymidine incorporation was determined as 
deacribed in section L of the Methods and Materials chapter. 
l>ffD, not deterained. 
cData are expressed as the mean stimulation index of triplicate cultures ± the 
standard deviation. 
'° I-' 
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LYD'Pl node proliferative :responsiveness of macrqilage derived 
Ilrl treated animals to the Eir-4 lyqilana, follc::Min;J the secorrlary 
turoor challerqe, was assessed. No pattem of lYD'Pl node prolifer-
ative responsiveness was noted followinJ periodic assessment f:ran 
five to fourteen days followinj the Eir-4 :rec.hal.lerqe. '!he greatest 
response generated by these animals in this time pericxi was seen on 
day seven (SI = 1.92). However, a statistically similar :response was 
also generated by c. parvum treated animals that were not given IIr 1 
therapy. 'lhese data in:iicate that Ilrl did not elicit aey detectable 
lYD'Pl node cell proliferative :response to the Eir-4 lyqilana followinJ 
either the primary or secorXlary turoor challerqe at the time periods 
assessed. 
OISCIJSSICN 
'1he use of cytokines in cancer innnunotherapeutic IOOdels has 
become increasinqly attractive as the importance of these intercel-
lular messenger ioolecules beccmes ioo:re arrl ioo:re awaz:ent in both in 
vivo arrl in vitro studies. '1he lOOOOkine, IIr-1, was chosen for study 
of inununaoodu.lation of the tunor imm.me :response due to the wide 
variety of biological activities associated with this protein (64, 
78). several. lines of evidence stroRJly suggests that IIr-1 may be 
able to positively mdulate the host :response to a neoplastic d1al.-
lenge. IIr-1 has been shown to augment .in vitro inm.me :responses by 
enhancinq the proliferation of T (48,177,192) am B lYJl'Plocytes 
(124,166,247), either directly or throogh the production of other 
ly.rrpiokines such as IIr-2 arrl gamma-INF (94,281). IIr-1 has been shown 
to enhance natural killer cell activity (115,239), oontribute to the 
generation of cytotoxic T lYJl'PlOCYtes (281), am augment antibody 
production both in YiY2 (166) am in yiYQ (285). IIr-1 irduces 
mac:rqilage prcduction of :EGE2 (68), arrl is involved in the activation 
of macrqilages to becane tunoricidal (240). IIr-1 has also been shown 
to be a chenX>attractant for macrqi'lages (170). Finally, IIr-1 has 
deloonstrated direct cytostatic am cytotoxic activity against sane 
tunor cell lines (168,235). 
Little direct eviden::e exists which inlicates a 
fUnctional role for IIr-1 in the host :response to neoplastic disease 
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or for the use of IL-1 as an inm.motherapeutc agent. 'lherefo:re, IL-
1 has been evaluated in this :researdl to assess the efficacy of IL-1 
as an immuncm:xiul.ator in an experimental neoplastic ll¥:del. In this 
lOOdel, IL-1 in oanj\.D'lCticm with local adjuvant therapy, has been 
deloonstrated to significantly enhmx:Je the tunDr inm.me response of to 
the EI.r4 lyn¢ana. 
Initial in vivo imnamoadjuvant tunx:>r protecticm studies usirg 
intradermal injections of heat-killed c. parwm admixed with an EI.r4 
tun-or challerxJe verified previous "WOrk (183,190) imicatirg that the 
use of nonviable bacterial imnunoadjuvant antitunx>r therapy was 
effective in protectirg C57Bl/6 mice fran an initial EI.r4 tun-or chal-
lerxJe. As dem::>nstrated previously, the tunx>r protective :response 
assooiated with bacterial adjuvanticity was enhanced in a dose depen-
dent manner, with 2 x io9 c. parwm cells enabliDj very high sw:vival 
against the EI.r4 tunx>r challe?XJe. 'lhe ability of EI.r4 cells to sur-
vive sixteen hours in in vitro suspensions of heat-killed~ parwm 
bacterial cells rcmJin:J in concentration fran 1 x io8 to 1 x iolO 
cells without loss of viability ,as shown in Table 2, strongly imi-
cates that the admixed heat-killed c. parvum cells were not toxic to 
the EI.r4 tun-or cells upon in vivo challerxJe. 'lherefo:re, toxicity of 
the bacterial inum.moadjuvant utilized was not responsible for the 
observed protection. 
All C. parvu!ll treated animals I which SUJ:ViVed the initial EI.r4 
challerxJe am were given a secorxi EI.r4 dose without adjuvant therapy. 
As shown in table 3, these :rechalle?XJed mice all succumbed to the 
secom tunx:>r challerqe. 'lbese :results are in straq aq:reement with 
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previous absezvations which in:licate that highly noninm.mogenic 
tunv:>rs, such as the Eir4 lynpiaDa, fail to elicit protective bmm' 
immunity in anililal.s cured of a primacy bmm' challen:Je by adjuvant-
type inmmotherapy (80,249). 
It is ag>arent by viewirq Figure 1 that ~ parvum has the 
capacity to activate macrqilaqes to bmm'icidal. activity in a dose 
depeOOent manner. It is also ag>arent that this activatioo was JDl-
specific in nature since both Eir4 an:i RBtt-5 bmm' cells were both 
lysed by c. parvum activated JllaCJ:'qilages. 'lhese results are in 
agreement with previous work ~ that the antibmm' effect of 
~ parvum in YiYQ cm relatively noninummogenic tum:>r is the result of 
imnumologically nonspecific mechanisms (294). 'Ihe c. parvum an:i I.PS 
activators did not decrease the viability of the Eir4 tunv:>r cells 
when incubated together wit.halt the presen::ie of the PECs for the dur-
ation of the experiment. A decrease in ta%get cell viability was 
seen only when the I.PS concentration was increased to 100 q or ten 
times the maxim.nn anomt reported in these macrq:haqe activation 
experiments. 'lhese results suggest that one possible mechanism of 
antitunv:>r activity of c. parvum in this C57Bl/6 murine 100del is local 
c. parvu:m mediated activation of macrqilaqes leadin;J to tunv:>ricidal 
activity against the admixed Eir4 tunv:>r cells, an:i not as a result of 
direct toxicity to the injected tunv:>r by the bacterial adjuvant. 
'!here is also sufficient evidence to in:licate that c. parvum 
can prime mice for 'INF production ( 41, 112) • Serum oontainirq 'INF 
causes henK>rrtlaqic necrosis of DrJUSe an:i human tunv:>rs in vivo ( 41, 
111,113,316). AbJJDant evidence in:licates that the macrqilaqe is the 
96 
major source of serum 'INF with the dem:>nstration that peritoneal mac-
rophages produce 'INF-like activity after stimulation with emotoxin 
(150,184,263). Recent studies have shown that the tuioor variants 
which becane resistant to lysis by activated macrqilages have ac:xpir-
ed :resistance to 'INF. '1bese investigators also dJserved that 'INF-
neutralizirq antibody totally inhibited activated macrqilage mediated 
t.uioor cell lysis. '1bese results alOn:J with the known 'INF producirq 
capability of activated macrq:hages st:ronJly suggests that the ~ 
pazyum adjuvant therapy given EL-4 c.hallen;ed mice may activate 
macrqi'lages leadin;J to the production of 'INF. 'Ihus iniicatirq a 
nonspecific antitum:>r macrqilage mediated mechanism. which lead to the 
destruction of the primary tuioor. 
In rechallen;Je experiments which enpl.ayed systemic treatment 
with macrqilage derived IL-1 oanbined with the local administration 
of c. paryum, a marked enhancement in rechallen;Je SU?.Vival rates 
(53.5 percent) was seen in IL-1 treated animals. A significantly 
lower percentage of animals (20.5) which received~ paryum therapy 
without IL-1 survived a similar rechallen;e. Smvivirq animals that 
received only IL-1 therapy follCMirq the initial tuioor c.hallenge were 
also rechallen;ed. '1bese animals demonstrated a rechallenge survival 
rate statistically similar to animals which received~ paryum ther-
apy alone. 'lherefo:re, it appears that macrqilage derived IL-1 was 
able to enhance rechallen;e survival only in oonjl.lllction with local 
c. parvum therapy. 
In similar experiments utilizirq murine reoanbinant IL-1, a 
very high proportion of animals survived which received the EL-4 
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tum::>r challerge admixed with c. parvum, whether they received the 
111.Jrine reoanbinant IL-1 or the P388DlA culture supematants. Upon 
rechallerge of survivors fran each treatment group there was again an 
increase in survival rates amn:J mice that had received IIrl when 
oarpared to mice given the control P388DlA culture supernatants. 
Although the difference in survival rates between these two animal 
treatment groups was not statistically significant at p < o.os, the 
prolorqed survival cuzve produced by the reoanbinant IIrl treated 
mice imicated there was a an antitum::>r effect produced by the :reoan-
binant mlecule. statistical analysis verified the OOserved enhaooe-
ment of survival duratioo (p < O.Ol) in the reoanbinant IL-1 treated 
mice. SUrvival curves, shown in figure s, generated by rect\alletY;Jed 
mice that received the control P388DlA culture supernatants were 
essentially identical to control animals that received an initial 
tum::>r challerge without therapy. It therefore appears that :reoan-
binant IL-1 therapy was effective in generatin;J an antitum::>r response 
against the Eir4 rechallerge in oonjuootion with local c. parvum 
adjuvant therapy. 
In experiments utilizin;J macrqilage derived IL-1 no differe-
nces were awarent in survival rate of animals which received IL-1 
alone or in oonjunction with c. parvum when oarpared to the cor.res-
porrlin;J group of animals not receivin;J IL-1, nor did IL-1 extern the 
survival time of these animals. Only followi.rg a seconjazy tum::>r 
challerge was a significantly enhanced survival rate noted for IL-1 
treated animals, 'Whereas an enhanced survival duration was noted for 
animals treated with recanbinant IL-1. 'Ibis d::>seJ:ved antitum::>r 
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activity noted in IL-1 treated anilllal.s followirq the seccn:i tunor 
c.hallen;Je was associated with a marked increase in the number of 
lynp-iocytes in the lyitpl nodes drainin;J the site of the tunor c.hal-
len;Je. '!he altered lynphocyte distribution seen in the lyitpl nodes · 
drai.nirg the site of the Eir-4 rechallen;Je of IL-1 treated animals, 
suggests that these l}'ltiil nodes may well have hartx>red lyqiloid cells 
~·to the Eir-4 tunor. 
Eir-4 specific serum antibody titer was the initial illummolog-
ical parameter assessed in a series of in ~ experiments. tJrrler 
the corditions of the experiments performed in this study, there did 
not appear to be aey production of detectable antibody against the 
Eir-4 lynpiana in IL-1 treated anilllal.s within the first several weeks 
followiz:g the tunor c.hallen;ie. IL-1 treated mice considered cured of 
the primary Eir-4 c.hallen;ie also failed to elicit a detectable Eir-4 
specific antibody response 35 days after the tunor challen;ie. 
Unlike man, the ra?X]e of target cells susceptible to lysis by allo-
geneic leukocytes lttben sensitized with antibody is very restricted. 
M.lrine t:a?:qet cells sensitized with anti-IA antibody are generally 
unharmed by IOOUSe leukocytes, as determined by the chranium release 
assay, althalgh. the possibility of lon:J-term damage has not been 
ruled out (19). '!he lack of aey significant IL-1 imuced antibody 
titer against the Eir-4 lynt;ilana, canbined with the generally poor 
sensitivity of murine cells to antibody deperdent cellular cytotoxic 
ity ( 19) , makes this an unlikely mechan:l.sm acx:nmtirq for the anti-
tunor activity associated with IL-1 treatment. 
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EI.r-4 specific T cell nwediated cytotoxicity, was also shown not 
to be enhanced by the administration of IL-1. 'lhe irduction of cyto-
toxic T cells in the lynqil nodes arxi spleens of mice treated with or 
without IL-1 was assessed in this system, followirg either the prim-
ary tum::>r challe.DJe or after animals cured of the initial challen;Je 
received a secon:1aJ:y tum::>r challe.DJe. Cytotoxic T cells directed 
against the EI.r-4 l:ynpnna producirg cytotoxic activity greater than 
one L. u. was not obseJ:ved in arr:t of the treatment protocol animals 
includirg the animals given IL-1. '!his data, taken together with the 
obseJ:ved lack of augmented hun:>ral .inum.mity in IL-1 treated mice, 
suggests that the augmentation of antitum::>r activity seen in these 
animals may have resulted frau the generation of naispecific anti-
tum::>r effector mechanisms. 
Although recent eviderx::e imicates that IL-1 nay enhance NK 
activity of large granular lyq;.hocytes (IGis) (115,239), there was no 
apparent in::rease in NK activity after the primary tum::>r challe.DJe. 
'lhese results were seen for both spleen arxi lynqil :rX>de cell pcpila-
tions in c. parvum treated animals given either macrqilage derived or 
recanbinant IL-1, when oarpared to animals 'Which received EI.r-4 alone 
or EI.r-4 admixed with ~ parvum. Splenic NK activity observed for 
each of the various treatment groups of mice followinq the primary 
tum::>r challe.DJe, as expressed in lytic units, ~to fluctuate 
fran day to day. However, the results for the different treatment 
groups within each day's experiment showed less fluctuation with no 
pattern of arr:t significant irx:reased or decreased levels of .NK activ-
ity for IL-1 treated animals. Very low levels of NK activity (less 
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than one L. u. ) were roted for lynqil ncxie cell pc:p.ll.atioos of ~ 
parn.nn plus IL-1 treated animals as well as ooutrol animals that 
received Eir-4 alone or EL-4 admixed with ~ parvum. 'lhus, IL-1 
treatment did not appear to augment the NK responsiveness of mice 
after the initial d'lallen:Je. 'Ibis is not surprisin;J oonsiderin;J the 
lack of enhanced sm:vival of IL-1 treated mice follarln;J the initial 
't:unDr c.hal.len;re. 
Assessment of spleen arxi lynqil ncxie cell NK activity, follow-
in;J the Eir-4 rechallen:Je of animals treated with local~ parvum 
therapy plus either reoanbinant IL-1 or macrophage derived IL-1, 
dem:>nstrated very low levels of NK activity. Control animals which 
received c. pazyum therapy plus HSA injectioos showed similarly poor 
NK responsiveness. '!he lack of IL-1 enhanced NK activity may have 
been due to the low dosage of IL-1 utilized in this system. More 
recent evidence suggests that BRM-in:iliced increases in NK activity in 
other organs such as the liver is partially due to an increase in IGL 
cell mnnbers which ooours by a ccanbination of IGL proliferation arxi 
an influx of IGis via the blocxi (32,125,179). FUrt:her investigation 
has suggested that the hyporesponsiveness of NK activity which is 
in:iuced in the blocxi arxi spleen by repeated administratiai of sane 
BRMs, may by partially due to a redistributicm or diversicm of NK 
cells fran those sites (288). 'lherefore, the possibility remains 
that IL-1 treatment may irxieed have in::reased NK activity in this 
system, but at sites not relevant to those tested in this disser-
tation research, e.g., the localized lynqil nodes drainirq the tUIOOr 
site arxi the spleen. 
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Splenic popll.ations fran Eir4 rechallaged mice cured of the 
initial tunor chal.len;ie with the cx:mbination c. paryum plus either 
:recanbinant or macrqi1age derived P388DlY IL-1 therapy ltt'ere irx::ubated 
in the presen::ie of EL-4 stimJ]ator cells, am assayed for prolifer-
ative responsiveness to the tunm'. No proliferative responses ltt'ere 
noted in splenic populations ci:>tained fran mice prior to the EL-4 
tunor rechallerge. However, lyqila-proliferation did cxx:ur in spleen 
cell taken f:ran mice several days after the seoord exposure to tunm' 
antigens for the secxni time. Proliferative responsiveness to the 
tum:>r was d:lserved in spleen cell taken fran mice up to six days 
after the EL-4 rechallen;ie. '!he same spleen cell pc:pllatians fran 
IL-1 treated animals which respaOOed to the EL-4 stinul.ator cells did 
not respom to the ~iate YAC-1 stinul.ator cells. Similarly 
rechalleI'.ged control anhnal s which survived the initial Eir4 chal.-
lerge with the aid of~ parvum therapy in oambination with HSA 
injections ltt'ere unable to respord as stron;Jly to the Eir4 cells three 
days after the rechallerge, am not at all six days after the secom 
1:unm' chal.lerge. Spleen cells f:ran these animals ltt'ere likewise not 
able to resporxi to the YAC-1 stinul.ator cells. 
'!his IL-1 augmented proliferative response may well be a sig-
nificant inilcator pointinJ to the role of IL-1 in the capacity as an 
antitunor agent (240) • studies in other syn;Jeneic tunor JOOdel. sys-
tems have shown stron;J correlations between acquisition of cutaneoos 
delayed-type hypersensitivity :reactivity, mac:rqMge migration inhib-
ition, am lyq;bocyte blastogenesis to tmoor antigens (194) •. Alaq 
with the good oorrelation between these activities, the responses 
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were shown to be tuiror-line specific an:l dose depement (194) • 
'Iherefore, this enhanced splenic response observed in IL-1 treated 
animals points to a possible tuiror specific response capable of 
augmentirg a variety of antitumr mechanisms. '1hese responses may be 
initiated by migrato:r.y inhibition (170) an:l activatioo of nonocytes, 
leadin:J to enhanced antigen presentatiai. An enhanced presentatioo 
of EL-4 antigen may in tum lead to the irxiuctiai of IL-2 or ganma-
interferai. '1hese BRMs are both capable of anti-tunm' activity, an:l 
further activatin;J !nm.me processes via the lyqilokine cascade (83) • 
'llle generatiai of an enhanced tumr specific response to the 
EL-4 lynphana in the spleens of IL-1 treated animals whicil received a 
seoorxi tuiror challerqe Wicates earlier IL-1 therapy at the time of 
the initial c.bal.lerqe may have irxiuced systemic mdul.ation of the 
imnrune system. Iack of proliferative responsiveness after the 
initial c.bal.lerqe may have been due to the ve:r.y low inm.mogenicity of 
the EL-4 tuiror (183,190). 'lbere is also the possibility that a t:uioor 
irxiuced sua;>ressive state, as seen in other systems (79,224) may have 
developed in these mice, thereby not allowirq the detection of activ-
ated cells potentially responsive to the t:uioor. 'llle lack of~ 
detectable in vitro augmentation of tuiror specific effector flmctions 
in lynphoid populations of IIr-1 treated animals, alon;J with the 
enhanc.ed proliferative response noted in IL-1 treated, EL-4 rec.hal.-
len;Jed animals, suggests that the EL-4 responsive lyqtloid cells may 
be enhancin;J another antituiror mechanism. Since the tuiror specific 
proliferative responses noted in spleens of IL-1 treated mice failed 
to generate ~ detectable enhanced tumor specific effector cell 
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functions, the enhanced survival suggests that DJ-1 may be lOOdul.atirg 
the :inunune system leadllg to a nonspecific mechanism of tunor control 
by the murine host. Recent studies have shown that lynpiokine activ-
ated killer cells (IAK) are capable of destroyin;J a wide spectrum of 
murine am human tunor cell lines in vivo am in vitro (81) • '!he .in 
vitro developnent of IAK cells requires the incubation of lyqiloid 
cells in the presence of DJ-2 (105), therefore, this type of activity 
would not have been detected by .in vitro assesmrents in this study. 
DJ-1 treated mice dem::>nstrated an enhanced lynpJOid proliferative 
response in the spleen, an area 'Well separated fran the site of the 
tunor challetXJe. '!his activatiai followirg a seoormry exposure to 
the EU-4 t.uioor st:nn:Jly inplies lyqiloid OZ"gan production of DJ-2, 
distant fran the site of tunDr challerge. It has been dem::>nstrated 
in mice that DJ-2 administ:ratioo results in the in vivo qeneration of 
IAK activity (215) • '1hus the likely augmentation of DJ-2 production 
followirg a secxni exposure to the tUioor at a site distant frail the 
tunor suggests a generalized :response, possibly leadllg to the irxiuc-
tion of IAK cell activity. Since irduction of IAK activity is asso-
ciated with lyqilocyte proliferation, this greater number of lyitpio-
cytes seen in the lYJIPl nodes drai.nin;J the site of the tunor chal-
letXJe imicates possible DJ-2 mediated proliferation am irduction of 
IAK activity. Al~ this :mechanism of tunor cell killin;J is not 
tunor specific in nature, antigen irduction of DJ-2 may 'Well have 
:resulted in an antigen specific manner, as imi.cated by the in vitro 
tunor specific splenic proliferation seen in DJ-1 treated mice after 
the EU-4 rechalletXJe. 
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'lhe lack of an enhanced proliferative response by lymph node 
cells cbtained fran IIrl treated mice followi.rq the secaOOary tum:>r 
challenge may have been a result of low percentage of macrophages 
detected in the reqional lymph node cell ~atioos followi.rq the 
i.d. injection of c. paryum. Without sufficient m.nnbers of macro-
phages in the in vitro incubation culture, the JOOdest proliferative 
responses noted in the splenic cultures may not ocx:ur due to the lack 
of a critical number of antigen presenti.rq cells in the lymph node 
cultures. '!here is also the possibility that a high proportion of 
EI.r-4 reactive lynphoid cells responsible for :meroory irrluction to the 
tum:>r may have migrated frail the tumr site to the spleen followi.rq 
the primary tumr challen:Je. '1he possibility also exists that the 
massive trawi.rq of lyq;ilocytes in the reqicmal lyqil nodes due to 
the c. paryum injectioo may have diluted Eir-4 reactive lyitp1ocytes to 
the point that they 'Wall.d not be detected in the thymidine inool:por-
atian assay at the cell ooramtratian utilized. '!his ~ also 
leads to the possibility that an elon;iated time frame of testi.rq 
after the secaOOary tumr challe?XJe may have allowed the Eir-4 reac-
tive cells to proliferate to the point of detectioo. 
Speculation as to why splenic proliferative responsiveness was 
seen inc. pa.tVUm plus IIrl treated mice am not in mice given only 
~ pa.tVUm may partially be explained by the events seen in other 
tum:>r JOOdels. Many reports have shown that suppressor T cells are 
generated in response to growth of a variety of imnumogenic tum:>rs 
(220) • In the P-815 tum:>r system studied by Robert North, mice de-
velop Ly 1-2+ T cells capable of tum:>r specific lysis of P-815 target 
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cells .in vitro, ard also capable of regress~ a P-815 tun-or in the 
early stages of developnent established in qamna-irradiated mice 
(224) • 'lbe developnent of this early cytolytic response quickly 
abates as a oonseqwnJe of the progressive developnent of!¥ 1+2-
Sl.JR)ressor T cells which wre capable of inhibiti?XJ the expression of 
passively transferred inmunity against an established. Because the 
EI.r4 lyntfilana is regarded as a weakly inm.mogenic tunDr, the time 
required to generate a detectable inm.me response may be prolon:JE!d 
such that the developnent of S\JR)ressor T cells followirg the primary 
c.hallen;Je may prevent the in:iuction of a :response sufficient to allow 
the develq:ment of .imm.mological menmy. However, IL-1 treated 
animals which survived the primary EI.r4 challen;e were able to gener-
ate a IOOderate in vitro splenic proliferative response to EI.r4 stim-
ulator cells soon after a secxni tunDr challen;Je, suggesti.n;J these 
mice had responied to the tun¥:>r durirq the primary challen;Je ard 
developed menmy as imicated by the splenic proliferation to EL-4 
tun¥:>r t:az'qets followirq the secorn tun¥:>r chall~. Evide:ooe imi-
ca~ Ilrl as an up regulator _for T helper cells ('lff) .in vitro while 
inhibi~ the generatial of T SUJ;PreSSOr cells {Ts) {75,78) suggests 
this mechanism of action may account for the proliferative activity 
seen in the IL-1 treated mice. Whether ('lff) is directly enhanced or 
(Ts) is inhibited alla.dD:j greater expression of {'lff) has not been 
elucidated. 'I.be ability of IL-1 treated animals in this study to 
proliferate in response to Eir-4 targets followin:;J the seoom tunDr 
c.hallen;Je imicates IL-1 may have enhanced the ('lff) pcp.ll.ation 
responiir¥J to the tunm' _at the time of the initial challen,;Je or 
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inhibited the qeneration of (Ts) to a degree, thus allc:Min;J the 
developnent of mem:>:cy to the tuloor. Upon rechallen;e the IL-1 treat-
ed animals were then able to generate a proliferative response sooner 
am with greater intensity then anilllals not given IL-1 or follc:Min;J a 
prima:cy challenge. 'Ihe results of splenic proliferation followinJ 
the prima:cy am seoozxJa:cy tuloor challenge distinctly show the type of 
pattem one would expect if this mechanistic scenario was followed. 
'Ihe IL-1 treated animals del.oonstrated a strcn;Jer am mre p:rol0D1ed 
response to Eir4 targets follc:Min;J the secaXJary tuloor challenge, 
while the mice not treated with II.rl showed a significantly weaker 
am shorter response. 
lD vivo antit.lm:>r effects of human recanbinant IL-1 alP1a, 
without the aid of other oorrespon:iin:;J adjuvant therapy have been 
reported against several inm.mogenic nurine bm:>r cell lines (33). 
An intra-tuloor (i. t.) sin;Jle injection of a ve:cy large dose of IL-1 
(2.5 x 105 units) was required to successfully regress a seven day 
old palpable Meth A sarcana tmoor. Intramuscular (i.m.) am i.v. 
therapy proved less suooessful, with protective :results attained only 
follc:Min;J seven daily injections at 2.5 x 105 units of IL-1 per 
injection. Intravenoos therapy at even higher doses did not lead to 
protection against the Meth A bmm'. Despite the large IL-1 doses 
enployed by these investigators, they surprisin;Jly reported no sign 
of macrosc:q>ic inflamnation at the site of the injectiC11S. Similarly 
high, i. t. , doses of IL-1 afforded mice protection against seven day 
old Bl6 melanana turoors, while even higher i. v. am i. m. IL-1 doses 
showed no protective efficacy. Several conceivable mechanisms may :be 
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:responsible for the high efficacy by the i.t. rcute. IL-1 may: have 
direct cytotoxic effects against the tun¥:>r cells, act directly on the 
tunm' cells so as to facilitate cytolysis by I.GIB, act as a cheDD-
tactic factor for Da'lOCYteS, anj/or augment ioonocyte bmoricidal 
activity (240). 
IL-1 has been deDK:>nstrat.ed to have .in vitro cyt:ostatic as well 
as cytotoxic (168,235) effects on several transfonned cell lines, 
suggestinq a possible direct .in vivo therapeutic effect against tumr 
develqnent. Direct .in yj,tro cytolysis of A375 human melanana am 
IB29 murine fibroblast cell lines was detected with reoanbinant IL-1 
c::cn:::entratiaw as lOlrl as 0.125 units of IL-1 per ml, with lytic 
activity peak:in:J at between cme am eight units per. ml. '!he minimal 
cytostatic IL-1 dose for the same cell lines was o. 5 units per ml, 
with the effect peaJd.n; at between two to four unitsjml. '!he IL-1 
serum levels required to achieve in vitro inhibitory effects may well 
have been reached with the .in vivo IL-1 protocols used in this stOOy, 
oonsiderin] that 10 units of IL-1 were administered per mouse per 
injection. However, at these relative reoanbinant IL-1 doses, 
between 1 to 12.5 units per ml, no significant in vitro proliferative 
inhibitory activity was c:i'JServed against Eir-4 lyitplana cells by 
recanbinant murine IL-1. Nor was any enhaB:::ement of proliferative 
activity noted by the Eir-4 cells. 'lhe maximal .in YiY'.Q IL-1 dosages 
attained in these miCl'OOlltures were greater than the irdi.vidual 
dosages injected into mice reoeivi.n;J IL-1 therapy. S.bnilar results 
were obtain for Meth A bmm' cell in vitro resistance to IL-1. '1hese 
cells were also not susceptible to .in vitro incubation with high 
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doses of the human reoanbinant II.r-1 alpha (M. Yamada, personal can-
munication) • Heix::e, II.r-1 did not delronstrate arr:t direct .in Yim 
antitunbr activity against the EL-4 iynpiana utilized in this study 
or against tum:>r suooessful.ly treated in other work. 
As shown in figuniS 4 arxl 6 respectively, neither :reoanbinant 
or P388DlY macrophage derived II.r-1 therapy, without protective c. 
pazyum therapy, was effective at suwressin:J EL-4 tumr pl.'Ogl:eSSion 
leadin:J to animal death. Taken together with the .in vitro results, 
it appears unlikely that .in vivo administered II.r-1 had arr:t direct 
antitunx:>r effect upon the intradeJ::mally injected EL-4 tum:>r cells 
used in this study. 
II.r-1 has also been :reported to have the capacity to enhance 
m::mocyte tumricidal activity via a EGE2 mediated mechanism (240) • 
II.r-1 ag;>arently augments the tumricidal activity of~ by 
enhancin;J the production of ~, which in tum is responsible for 
m::mocyte irxiuction of cytolytic activity (236) • since i. t. injection 
of II.r-1 was the mre successful route of administration in the Meth A 
arxl Bl6 lOOdels, arxl II.r-1 did not inhibit these cell lines at high .in 
vitro concentrations, this II.r-1 mediated mechanism might better 
explain the obseJ:Ved antitumr effect. 'lhe m::mocyte chelooattractant 
ability of II.r-1 might potentiate this mechanism against the tun-ors, 
sinply by increasin:J the number of bmoricidal cells at the tun-or 
site. However, as previously discussed for the direct II.r-1 antitum:>r 
activity of II.r-1, this mechanism also appears unlikely to have been 
an inportant factor oontri.b.Itin:J to the protection of C57Bl/6 mice 
against the EL-4 tumr. '!his assllllption can be readied for several 
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reasons. Firstly, IL-1 therapy was ineffective against the primary 
EL-4 tunDr challerge, the time at which this mechanism would nost 
likely be effective against the tunw:>r. seccnny, IL-1 was injected 
i.p. in protection protocols against the EL-4 tunw:>r, therefore, there 
is little reason to suspect these injections would cause an iIX:rease 
in nonocytejmacrq:i1age cell numbers at the tunw:>r site. 
'!he ability of reoanbinant IL-1 allila to protect against the 
weakly inum.mogenic oolm 26 adenocarcinana when treated with similar 
doses of reoanbinant IL-1 therapy (219) was mt as dramatic as that 
mentioned for the inum.mogenic Meth A. Althcu;Jh a significant de-
crease in tunw:>r mass was noted twenty-Q'le days follc:71li.nJ the bmm' 
challerge, tunw:>r q.cowth in these animals accelerated, eventually 
causi.rg death in these animals at approximately the same time as the 
untreated control animals. 'lherefore, IL-1 was \.ll'lable to cure 
animals of a non-inum.mogenic tunw:>r. 
Followi.rg IL-1 treatment, mice cured of the initial Meth A 
saroana were able to reject a redlallen]e with the same tunDr. In 
viert1 of the ooncurrent devel.qment of inma.mity in mice protected 
against inum.mogenic tunw:>rs, it is possible to suggest that IL-1 
lOOdulated tunw:>r specific mechanisnVs lead to the destJ::uction of 
inmnmogenic tunw:>:rs. Al~ these authors have suggested that IL-1 
is lNOrkin] in their system by inlirect antitunw:>r mechanisms, no in 
vitro assessments of inm.mological parameters associated with anti-
tunw:>r activity have been ccniucted to verify these assunptions. Also 
the IL-1 dosages required to obtain effective cure ratios in their 
system were only three to four fold urrler the IDso dose for naive 
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mice, suggesting the developnent of in vivo cellular toxic effects 
resulti.rg frc:an these doses (19). FUrtheim:>re, specificity of this 
tumr imm.mity was not detennined, since smvivin;J animals -were not 
rechallerqed with a tuJoor cell line other than that used for the 
prilnaey challen;Je (M. Yamada, personal cammmication). 'lherefore, 
the mechanism of IL-1 mediated antitumr effects at these large doses 
have yet to be explained. 
Although in vivo tuJoor protection studies showed that the 
llllrine reoanbinant IL-1 statistically enhanced the smvival duration 
of EL-4 rec:hal.len;Jed mice, the increased smvival rates d::>se:rved for 
IL-1 treated anjnels t.hen cxmpared to non-IL-1 treated animals was 
not sufficient to determine a statistical difference. '1here are sev-
eral possible explanatioos for not d:Jsezvin:] statistical differences 
in smvival rates in these .in yiYQ reoanbinant IL-1 protection 
studies. 
'lhe possibility that the recanbinant mlecule is not as bio-
logically active as the mac:r:qilaqe derived IL-1 employed for study in 
this dissertation research. 'Ihe recent p.irification of reoanbinant 
fonns of IL-1 has stirred speculation about the similarities am dis-
similarities dem:>nstrated by mnocyte or biologically derived am 
recombinant IL-1. 'Ihe biological activity of thfa llllrine reoanbinant 
IL-1 isolated by Peter I.anedioo (the same soorce utilized for the in 
vivo studies presented in this dissertation) ·has been reported to be 
pyrogeniC, causes hypozinoemia am leukocytosis I am d.eroonstrates in 
vitro IAF activity (219). Hor.\lever, the same authors foum that 
recombinant IL-1 alJ;i'la was not capable of increasin:J energy experd-
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iture or protein catabolism or anabolism. '!be reoanbinant fonn of 
IL-1 also failed to increase the acute piase proteins (291). '!be 
pyrogenic effect of the nurine reoanbinant !Ir 1 was also fooni to be 
delayed in ooset, although, the effect was eventually as potent as 
the naiocyte derived IIrl (282). 'lherefore, it appears that the 
recombinant molecule is not identical to the monocyte derived IL-1 
'Whose biological activities have been extensively outlined in the 
past. It is very possible that the recanbinant IL-1 molecule repre-
sents a pure protein expressed by one gene while the monocyte derived 
II.rl may represent a family of proteins each responsible for separate 
of overlappirx] biological activities. If this is the case, it is 
possible that the anti'tl.lmr effects of host or macrqilage derived 
IL-1 may act though mre than one specific mechanism, am that these 
effects may lead to aalitive or syne:tg'istic anti'tl.lmr activity. 
When workirq with a reoanbinant mlecule, there is al.so the 
possibility that lower level of activity associated with that :reoan-
binant mlecule is due to partial denaturatiai or in:::on:ect :renatur-
ation. 'Ibis does seem \.ll'llikely, however, since the recambinant ml.e-
cule does retain many of the biological activities associated with 
biologically derived IIrl. 
AnOther precaution VU.ch must be assessed when usirq :reoan-
binant materials derived frail L. coli is the potential of en:iotoxin 
contamination or reactivity to the reoanbinant protein storage bl:ffer 
(in this case guanidine hydrodlloride). In vivo analysis of reactiv-
ity to a similar concentration of a nonreoanbinant IL-1 recanbinant 
protein, made in E. QQl.i am p.irified in an identical manner to the 
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11¥:>USe recanbinant IL-1, caused no significant increase in any of the 
biological parameters assessed in Dllrine systems (219). Similarly 
negative results were obtained men the guanidine hydrochloride buf-
fer was also tested in this system. 'Ihe recanbinant protein am 
buffer concentration (0.008 M guanidine hydrochloride) tested in that 
system was over forty times greater than the concentrations which 
were injected with the reoanbinant IL-1 in experiments enployed for 
this research. 'lherefore, the recombinant IL-1; am not potential 
contaminatin:;;J errlotoxin, bacterial prot.eins, or bufferirg reagents; 
appear to be responsible for the enharx::ed anti'b.uoor activity observed 
in this system. 
Although reoanbinant IL-1 appeared to be less active in this 
system accordirg to statistical analysis of su:r.vival rates, there is 
the possibility that other biological response lOOdifiers in the 
macrophage derived IL-1 sanples may be involved in p:roducirg additive 
or synergistic anti'b.uoor effects. 'Ihe eviderx:le produced in this 
research does not SUR;>Ort the idea of additive antit.um:>r effects of 
other potential BRMs in the macrqilaqe derived IL-1 oontaini.rq cul-
ture supematants, since no antitum:>r response was reflected in the 
su:r.vival data. control animals treated systemically with unsti:au-
lated macrophage culture supematants died followin;J EL-4 rec:hallerge 
while a significant number of animals that received IL-1 treatment 
were able to su:r.vive. Fllrt:henoore, the su:r.vival curve generated for 
these control animals was no different frau animals that received a 
primary EL-4 'b.uoor challen:Je without the aid of any therapy, suggest-
irg that other BRMs in the macrqi'lage derived culture supematants 
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were solely responsible for the a\¥]lDE!l\ted antitunm' effects. 
'1hese results do rx>t eliminate the possibility of synerqistic 
effects by nr 1 am other BRMs produced by the P388Dl macrophaqe cell 
line. Granulocyte-Macrophaqe Colony stinlll.atin;J Factor (Gt-CSF), a 
macrophaqe product, has been fann to be produced by cell lines 
established fran myelcmn:x:ytic leukemias (175). It was rx>t sur-
prisin3' when work c::axpleted in Rita Yourg' s lal::Joratory denalstrated 
that CSF was fann to be in the P38801Y, IIrl oontainin;i culture 
supematants (Rita Yourg, persaial. CXllllllnication, data rx>t shown) • 
'!be ability of this BRM to stim.Jlate cell division, am ultimately 
the number of fuootionally mature grarrul.ocytes am mac:rqil21ges avail-
able to the host for effector or accessory cell fuootion, may allow a 
100re effective response to occur in response to the EU-4 tunm' chal-
l~e. 'Ibis is a distinct p:>ssibility an:i, if true, may account for 
the significantly augmented survival rates rx>t seen solely with the 
:murine reoanbinant material. 'lbere is also the possibility that 
further experimentation with larger groups of animals may allow the 
expression of statistical differences in survival rates between the 
different treatment groups which were rx>t awarent in these st\.dies. 
An alternative or synerqistic mechanism of acticn which may 
help account for the enhanced IIrl a~tion of inmmi.ty in this 
turoor system revel ves aroom the observation that IIr 1 administraticn 
elicits radioprotective capabilities in the :murine system (222). 
Many bacterial agents, such as BOO, IPS, nuramyl dipeptide am glucan 
have radioprotective effects am are potent irducers of IIrl, known 
to elicit radioprotective effects if delivered before irradiaticn 
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(314). Al.though the exact basis for this protective effect has not 
been clearly established, it has been postulated that these effects 
are a result of heloopoietic enhancement by IIrl, since previous work 
has in:licated that cells in the late s i;ilase of the cell cycle are 
:mre resistant to irradiatiai dmnaqe (279). 'lhe capacity of IIrl to 
initiate the irxiuctiai of the a cascade of lyq;hokines sudl as CSF 
am IIr2 may lead to the develcpuent of various lYllliloid cells by 
imucirg hematopoietic progenitor cell populaticms into the s i;ilase 
of the cell cycle, thereby llx::reasirg the rrumber of potential anti-
tunor reactive lynpiocytes or mnocytes. As described earlier, 
macrophage derived IIr 1 was :mre effective in protectirg mice fran 
the second tunor challerge. 'lhis effect may have resulted frail 
synel:9istic activities of IIrl with other lynpioJdnes associated with 
macrophage ooniltioned medium. As mt:e earlier, CSF was shown to be 
associated with the macrqi'lage derived IIr 1. '!he synel:9istic activ-
ity between these two lOOl'lOkines may have resulted in nmilizatiai am 
developnent of either IAK effector cell or Eir-4 reactive helper T 
cell populatiais, leadi.n;J to an enhanced level of protectiai noted in 
the macrophage IIr-1 experimentation. In contrast, the reoanbinant 
IIr-1 without the associated CSF or other macrophage m::>nokines was 
ally able to prolong survival duratiai while the macrophage product 
was able to enhance survival. If irrleed, IIrl am other macrophage 
products acted synel:9istically against the Eir-4 tunor, IIrl a~ 
to be the main factor in this activatiai process. 'lhis is ~' 
since mice which received P388DlA macrophage ooniltioned culture 
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medium contai.ninj CSF, but, little or no IL-1 denrmstrated no anti-
tunvor activity, while purified IL-1 did p:rolorq survival. 
In view of the results obtained for this dissertation it is 
ai;pmmt that IL-1 is capable of m::dul.atirq the 'b.m¥::>r inunune :response 
generated against the weakly inunogenic Eir4 lyqilal\a, in a system 
where no previous p:rotecti~ response had been seen against a secom.-
ary t:uioor c.h.al.lerqe. Althalgh IL-1 had no disoernal:>le in vivo pro-
tective effect against the primary Eir4 t:uioor c.h.al.lerqe, IL-1 was 
able to m::dul.ate the response to the t.uioor, enablirq an enhanced 
population of mice to respcni 100re successfully against a seoord 
c.h.al.lerqe. 'lhis IL-1 in:iuoed antit.uioor activity was effective only 
when IL-1 therapy was provided in conjunctiai with the protective ~ 
parvum adjuvant therapy. '!he enhanced protective effect observed 
against the primary Eir4 c:hallerqe appears to be a result of ~ 
parvum mediated a~tion of macrophage tunvoricidal activity 
(162). '!he enhanced number of lynpioc::ytes observed in the regional 
lymi;il nodes of IL-1 treated animals followirq the seconi Eir4 t.uioor 
c.h.al.lerqe, st:rorqly suggests that the lyqiloid population, originally 
recruited to the lYll'Pl -nodes drainirq the tuloor site by the subcutan-
eous adjuvant injection (201), were m::dul.ated by IL-1. IL-1 's 
imnumoadjuvant activity (285) may have allowed the ll1l.lrine lynpiocytes 
to respond to the tuloor antigens 100re.rapidly and effectively before 
antigen rerocwal.. At the same time IL-1 's ability to induce hemato-
poietic progenitor cells (222) may have also increased the number of 
potential lynphoid effector cells available for recruibnent to the 
t.uioor site. '!he Eir4 specific splenic proliferation seen in IL-1 
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treated anllnals again suggests lynphocytic involvement, possibly in 
effector an:t;or helper capacity. '!he lack of detectable Eir-4 specif-
ic htn00ral or cellular antitmoc>r mechanisms such as, augmented serum 
antibody titers or T cell cytotoxicity against the Eir-4 lymphoma, 
suggests the potentiation of non-specific antitmoc>r mechanisms by 
IL-1. No detectable increase in NK activity, was noted in IL-1 
treated animals. However, an alternate non-specific mechanism which 
would be an effective means of destroyfn.1 the Eir-4 tmoc>r is the 
developnent of IAK cells, which demonstrate in vitro lytic activity 
against an extremely wide raIXJ8 of b.noors (81). 'lhe splenic prolif-
erative response to the Eir-4 tumr strcn.1ly ~ splenic am 
possibly systemic lyn;iloc'Jtic pl.'Oductian of IL-2 (83,140), the BRM 
necessary to generate effective IAK activity .in vivo (105) • 'lhe 
largest arxi IOOSt prolonged proliferative response to Eir-4 follc::iwin] 
the secon:3ary tmoc>r c.hallen;ie was seen in IL-1 treated animals, 
suggestfn.1 the possible irnuction of this effector mechanism in IL-1 
treated mice. 'lherefore, the IL-1 treated mice 'Walld convert the 
enhanced tmoc>r specific proliferative response to the non-specific, 
IAK mechanism, for b.noor eradication. 
Although interleukin 1 (IL-1) has been shown to :function as an 
innm.mological adjuvant in defined antigenic systems, there is little 
evidence suggestin;J a protective role for IIrl in neoplastic dis-
eases. 'lhis investigation de:rronstrates that intraperitoneal (i.p.) 
injection of macrophage derived IL-1 significantly enhanced inununity 
of C57Bl/6 mice to the weakly inmunogenic EL-4 lyq:hana. Mice given 
an intradennal injection of the Eir-4 lyqnana admixed with c. parvum 
showed a high survival rate. Aniinals identically c.hal.len;Jed, wt 
given i.p. macrophage derived IL-1 (100 units/animal) showed similar 
survival. However, upon subsequent reohallen;Je of these mice with 
the EL-4 lynphana alone, the gra.ip given IL-1 denrAnstra.ted a markedly 
enhanced survival rate (p < 0.01) cxmpared to the groop not qiven 
IL-1. Mice given murine reccmbinant IL-1 in conjunction with~ 
parvum, denalstrated a statistically enhanced survival duratioo 
following a secomary t.unx:>r c.hal.len;Je (p < o. 02) when oarpared to 
animals given c. paryum wit.halt IL-1. SUrvival rates of mice c.hal.-
lerqed with the EL-4 turor an:i administered only i.p. IL-1 (macro-
P1age derived an:i murine reccmbinant) showed no statistical differ-
ence to animals c.hal.len:Jed with the turor alone. '1hese results 
strol'X}ly suggest that IL-1 may :function to augment turor inununity 
when administered systemically, in conjunction with local administ-
ration of c. paryum. 
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lD vitro assessment of EL-4 specific antibody titer, natural 
killer cell activity, am EL-4 specific cytotoxic T cell activity of 
IL-1 am non-IL-1 treated mice denonstrated no detectable IL-1 imuc-
ed augmentation of these hunr>ral or cellular effector cell functions. 
A marked iJx:rease in lYJl'Pl node cell rrumbers obtained f:ran 
lyqil nodes drainin;J the bnoor dlallerqe site of IL-1 treated mice 
following the secorX!aJ:y bnoor dlallerqe, suggested a lyirphoid cell 
migration or a lynphoproliferative response in these lyqil nodes 
followirg the secom EL-4 tumr dlallerqe. Both macrqilage derived 
(p < 0.001) or murine recombinant (p < 0.05) IL-1 treated mice also 
dem::>nstrated an enhanced EL-4 specific lynphop:roliferative respons-
iveness in their splenic cell pop.llations. '!his IL-1 iniuced, 
splenic proliferative response, oambined with the lack of 8rf;1 obser-
ved IL-1 iniuced tumr specific effector cell response, stron:Jly 
suggests an IL-1 enhanced tumr specific augmentaticm of a non-tumr 
specific mechanism of tumr killirg • 
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